

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 473/00, 473/34, C07K 5/08, A61K 31/52		A1	(11) International Publication Number: WO 95/35297 (43) International Publication Date: 28 December 1995 (28.12.95)
(21) International Application Number: PCT/CA95/00356 (22) International Filing Date: 21 June 1995 (21.06.95) (30) Priority Data: 08/264,028 22 June 1994 (22.06.94) US (60) Parent Application or Grant (63) Related by Continuation US 08/264,028 (CIP) Filed on 22 June 1994 (22.06.94) (71) Applicant (for all designated States except US): BIOCHEM PHARMA INC. [CA/CA]; 275 Armand Frappier Boulevard, Laval, Quebec H7V 4A7 (CA). (72) Inventors; and (75) Inventors/Applicants (for US only): PENNEY, Christopher [CA/CA]; 141 Stephanie Street, Dollard-des-Ormeaux, Quebec H9A 3C1 (CA). ZACHARIE, Boulos [CA/CA]; Apartment 301, 595 de Largentiere, Laval-des-Rapides, Quebec H7N 4A1 (CA). GAGNON, Lyne [CA/CA]; 1973 de la Victoire, Laval, Quebec H7M 3E5 (CA). ATTARDO, Giorgio [CA/CA]; 2740 Prudential Street, Laval, Quebec H7K 3M1 (CA). CONNOLLY, Timothy [CA/CA]; 12245 de St-			Castin Avenue, Montreal, Quebec H3M 2L6 (CA). ST-DENIS, Yves [CA/CA]; 3727 St-Hubert Street, Montreal, Quebec H7L 3Z9 (CA). KADHIM, Salam [CA/CA]; 454 Ste-Dorothée Boulevard, Laval, Quebec H7X 1H6 (CA). ELY, Guy [CA/CA]; 79 Acres Street, Kirkland, Quebec H9H 5B5 (CA). (74) Agent: MBM & CO.; 1000 - 100 Sparks Street, Ottawa, Ontario K1P 5B7 (CA). (81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).
Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>			
(54) Title: NOVEL SUBSTITUTED PURINYL DERIVATIVES WITH IMMUNOMODULATING ACTIVITY			
(57) Abstract <p>The present invention covers substituted purinyl compounds. In particular, the present invention concerns 6-substituted purinyl alkoxycarbonyl amino acids, more particularly arginine derivatives. The present invention further includes substituted purinyl compounds which stimulate the immune system and thereby help protect the body against pathogens and cancer.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

NOVEL SUBSTITUTED PURINYL DERIVATIVES
WITH IMMUNOMODULATING ACTIVITY

5

Field of the Invention

The present invention covers substituted purinyl compounds. In particular, the present invention concerns
10 6-substituted purinyl alkoxycarbonyl amino acid compounds, more particularly arginine derivatives.

Background of the Invention

15 The primary function of the immune system relates to the protection of the body from disease. The immune system protects against not only those diseases which result from an attack by bacteria, viruses, and other pathogens, but also cancer, as well as disease states which result from
20 immune imbalance, opportunistic infections, or autoimmune disorders.

Modulation of the immune system through pharmaceutically induced stimulation or suppression offers an important
25 approach to the control of disease. Compounds which non-specifically stimulate the immune system are of potentially significant medicinal importance and have been the object of a lengthy research effort. Often, the research results show that immunomodulating compounds are
30 either weak immunostimulants, and hence not very effective, or potent immunostimulants and, therefore, effective but toxic by virtue of this potent immunostimulating activity.

Among the many classes of compounds which non-specifically stimulate the immune system are nucleosides which are well known in the art. For example, 7-thia-8-oxoguanosine has
5 been described by D.F. Smee et al. in the Journal of Biological Response Modifiers, 9, 24-32, 1990 as an antiviral agent in mice. The activity of this compound is derived from its ability to activate NK and B cells in the immune system, and to induce interferon. However,
10 subsequent antiviral studies in humans as reported by P.G. Higgins et al. in Antiviral Chemistry and Chemotherapy, 2, 61-63, 1991, have disclosed few encouraging results. One problem has been the lack of oral bioavailability.

15 Other nucleosides have been synthesized and studied in an effort to develop an improved medication. For example, D.F. Smee et al. report in Antimicrobial Agents and Chemotherapy, 35, 152-157, 1991, that 7-deazaguanosine has significant immunostimulatory and antiviral activity after
20 oral administration. However, these results are preliminary. With many nucleoside compounds, toxicity is an important issue which must also be closely analyzed.

A particular class of nucleoside immunostimulants has
25 arisen from inosine and other similar hypoxanthine-containing compounds. A well know example is isoprinosine, an inosine-containing complex. Isoprinosine has been thoroughly studied as an immunomodulator and referred to as a "gold standard" by C.D. Simone et al. in
30 Thymus, 19, 51-55, 1992. Some rationale for the activity of hypoxanthine- (inosine) containing compounds arises from the observation that a lack of adenosine deaminase, the enzyme which converts adenosine to inosine, results in severe combined immunodeficiency disease (SCID).

Although very nontoxic, isoprinosine is not an effective immunomodulator, and in order to improve its immunopharmacological properties, numerous analogues have
5 been synthesized, as reported by J.W. Hadden et al. in International Journal of Immunopharmacology, 13, 49-54, 1991 (suppl. 1). In particular, they describe a prodrug in the form of inosine 5'-monophosphate (inosine, unless complexed, has little *in vivo* activity) and methyl inosine
10 monophosphate (MIMP). However, MIMP is not a very active immunomodulator.

In an effort to retain the nontoxic properties of isoprinosine, but enhance the immunostimulatory activity,
15 an immunomodulator was synthesized which contained both hypoxanthine and the amino acid L-arginine covalently linked by a pentamethylene bridge. The compound, ST 789 (hypoxanthine pentyloxycarbonyl L-arginine, formerly PCF 39) has been thoroughly described in a recent issue of
20 Thymus, 19, S1-S112 (1992). L-Arginine was selected because it is known to play a role in immune activation and is present at the terminus of many immunomodulatory peptides such as tuftsin, substance P, thymopentin, and splenopentin. ST 789 is further described in European
25 Patent Application #91830284, publication #464,009, published January 2, 1992. Analogues of ST 789 are also described in the European publication where oligopeptides composed of naturally occurring L-amino acids replace L-arginine. However, the purine base portion of the
30 molecule remains hypoxanthine.

While no immunological comparison was made with isoprinosine, a similar pattern emerged. The compounds are nontoxic but, at best, moderate immunostimulants. For

example, there was no indication that ST 789, or analogues thereof, could stimulate an important immune cell subset such as cytotoxic T lymphocytes (CD8⁺ T cells). This subset plays a key role in the defense of the body from
5 viral infections and cancer.

P. Cornaglia-Ferraris describes still another analogue of ST 789 in International Journal of Immunopharmacology, 13, 1005-1012, 1991. In the published compound, L-arginine is
10 replaced with the bombesin carboxy terminus dipeptide L-leucyl L-methionine. The purine base remains hypoxanthine. In fact, in this class of compounds where a purine base is covalently linked by a methylene chain to an amino acid or an oligopeptide, very little data has
15 been reported for compounds including a purine base other than hypoxanthine. Further, because of the requirement for physiologically active amino acids in mammalian systems, all the work reported to date describes amino acids of the (natural) L-configuration. One brief
20 description of the replacement of hypoxanthine with the naturally occurring purine bases adenine and guanine is reported by R. Stradi et al. in Fl. Farmaco, 45, 39-47, 1990, but there is no indication of significant biological activity.

25

As noted above, adenosine deaminase, and by implication inosine, is necessary to maintain normal immune status. Therefore, in U.S. patent 5,272,151 issued December 21, 1993, M. Marzi et al. reported that in ST 789 the
30 hypoxanthine is replaced with the xanthine oxidase inhibitor allopurinol. The result is ST 689, allopurinol pentanol. This substitution is expected to increase the concentration of inosine in vivo since inosine is catabolized to xanthine, and then uric acid in mammals in

the presence of xanthine oxidase enzyme. However,
allopurinol was noted to be immunosuppressive and ST 689
was not significantly more immunostimulatory than ST 789
in most of the immunology assays reported in the '151
5 patent.

Levamisole is another immunoregulator agent used against
malignant melanoma. It has now been found that levamisole
induces serious thrombocytopenia after starting adjuvant
10 levamisole therapy for malignant melanoma [Med. Pediatr.
Oncol. Apr 1995, 24 (4), 262-4].

The prior art indicates that there is a need for compounds
which have the ability to stimulate a number of immune
15 cell subsets and thereby possess significant
immunomodulating activity, but, at the same time, lack
toxicity.

Summary of the Invention

20

In accordance with the present invention, there is
provided a compound which possesses significant
immunostimulatory capability both *in vitro* and *in vivo*.


25 Specifically, there is provided a compound which possesses
activity in increasing the amount of cytotoxic T cells in
vitro and *in vivo*.

In another aspect of the invention there is provided an
30 immunomodulatory compound which does not have significant
toxicity and, in particular, does not have the toxicity
which is associated with significant or potent
immunostimulation.

In another aspect of the invention, there is provided an immunomodulatory compound possessing a purine derivative which is not a natural base.

- 5 In a further aspect of the invention, there is provided a compound which acts as a control against tumor growth.

The present invention includes compounds of formula (I):



10

(I)

- or pharmaceutically acceptable derivatives thereof, wherein
 R₁ is selected from the group consisting of hydrogen; C₁₋₁₆
 alkyl; halogen; substituted or unsubstituted thiol;
 15 unsubstituted or substituted amino; and OR⁸ wherein R⁸
 is selected from the group consisting of hydrogen, C₁₋₁₆
 alkyl, C₁₋₈ acyl, and C₇₋₁₈ aryl;
 R₂ and R₃ are independently selected from the group
 consisting of hydrogen; C₁₋₄ alkyl; amino; substituted
 20 or unsubstituted thiol; and halogen; and
 R₄ is selected from the group consisting of a linear or
 cyclic carbon chain of the formula (CH₀₋₂)₀₋₂₀ -X¹²
 optionally interrupted with one or more heteroatom, and
 optionally substituted with one or more =O, or =S, and
 25 wherein X¹², is selected from the group consisting of
 hydroxy, an aminoalkyl group, an amino acid, or a
 peptide of 2-8 amino acids,
 with the proviso that, when R₁ is NH₂, and R₄ is pentyloxy
 carbonyl-L-arginine, then R₂ is not hydrogen, and
 30 when R₁ is OH, and R₄ is pentyloxycarbonyl-L-arginine, then
 R₂ is not NH₂.

The following definitions are used herein.

The term "alkyl" as employed herein includes both straight and branched chain radicals, for example methyl, ethyl,
5 propyl, isopropyl, butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethylpentyl, nonyl, decyl, undecyl, dodecyl, the various branched chain isomers thereof. The chain may be saturated or unsaturated and may contain, for example,
10 double and triple bonds. The alkyl may be interrupted or substituted with, for example, one or more halogen, oxygen, hydroxy, silyl, amino, or other acceptable substituents.

15 The term "aromatic or non-aromatic ring" as used herein includes 5 and 6 membered aromatic and non-aromatic rings uninterrupted or interrupted with one or more heteroatom, for example O, S, SO, SO₂, and N, or the ring may be unsubstituted or substituted with, for example, halogen,
20 alkyl, acyl, hydroxy, aryl, and amino, said heteroatom and substituent may also be substituted with, for example, alkyl, acyl, aryl, aralkyl.

The term "acyl" as used herein refers to carbonyl groups
25 of the formula -COR wherein R may be any suitable substituent such as, for example, alkyl, amino, halogen, thiol, oxygen, hydroxy, and hydrogen.

The term "aryl" as employed herein refers to monocyclic or
30 bicyclic aromatic groups containing from 6 to 10 carbons in the ring portion, such as phenyl, naphtyl, substituted phenyl, naphtyl, substituted phenyl or substituted naphthyl, wherein the substituent on either the phenyl or

naphthyl may be for example C₁₋₄ alkyl, halogen, C₁₋₄ alkoxy, hydroxy or nitro.

The term "aralkyl" as used herein refers to alkyl groups
5 as discussed above having an aryl substituent, such as
benzyl, p-nitrobenzyl, phenethyl, diphenylmethyl, and
triphenylmethyl.

The term "substituted amino" as used herein refers to an
10 amino which may be substituted with one or more
substituent, for example, C₁₋₈ alkyl, C₁₋₈ acyl, C₆₋₁₂ aryl,
hydroxy, and hydrogen.

The term "amino acid" as employed herein includes and
15 encompasses all of the naturally occurring amino acids,
those amino acids in their D- and L-configurations, and
the known non-native, synthetic, and modified amino acids,
such as homocysteine, ornithine, norleucine and β -alaline.
A list of non natural amino acids may be found in "The
20 Peptides", vol 5, 1983, Academic Press, Chapter 6 by D.C.
Roberts and F. Vellaccio.

The term "linear or cyclic" when used herein includes, for
example, a linear chain which may optionally be
25 interrupted by an aromatic or non-aromatic ring. Cyclic
chain includes, for example, an aromatic or non-aromatic
ring which may be connected to, for example, a carbon
chain which either precedes or follows the ring.

30 The term "pharmaceutically acceptable derivative" as
employed herein, includes any pharmaceutically acceptable
salt, ester, or salt of such ester, of a compound of
formula I or any other compound which, upon administration
to the recipient, is capable of providing (directly or

indirectly) a compound of formula I or an active metabolite or residue thereof.

5 Brief Description of Drawings

Figure 1 illustrates the variations in tumor growth for mice treated with cyclophosphamide, or compound #1, or both.

10

Figure 2 illustrates the body weight variations for mice treated with the same regimen as in Figure 1

15

Figure 3 illustreates the variations in tumor volume for mice treated with Cytosan, or compound #1 , or both.

Figure 4 illustrates the body weight variations for mice treated with the same regimen as in Figure 3.

20

Figure 5 illustrates the variations in tumor volume for mice treated with 5FU, 5FU with levamisole, and 5FU with compound #1.

25

Figure 6 illustrates the growth curves of male Fisher rats treated with compound #1 at high doses.

Figure 7 illustrates the growth curves of female Fisher rats treated with compound #1 at high doses.

30 Description of the Invention

In one aspect of the present invention, there is provided a compound of formula (I) wherein R_4 is $(CH_2)_{1-8}-X^{12}$, wherein X^{12} is OH.

In a further aspect of the invention, there is provided a compound of formula (I) wherein R_4 is $(CH_2)_n-L-O-CO-X^{12}$, wherein L is a linear or cyclic carbon chain optionally interrupted with one or more O, S, or NH.

Preferably, X^{12} can be $(CH_2)_nNH_2$ wherein n is an integer between 1 and 6. More preferably, n is 2.

More preferably, X^{12} can be a naturally occurring amino acid in the D- or L- configuration. Preferably, these amino acids can be selected from the group consisting of: arginine, glycine, alanine, glutamic acid, valine, ornithine, or citrulline, or conservative substitutions thereof.

Still, more preferably, the amino acid is L-arginine. Even more preferably, the amino acid is D-arginine.

In an alternative embodiment of the invention, X^{12} may be a peptide of 2 to 8 amino acids.

Preferably, such a peptide can be Val-Pro-Leu, or Ile-Pro-Ile, or conservative substitutions thereof.

In another embodiment of the invention, L can be selected from: $-(CH_2)_n-$, $-(CH_2)_m-H-(CH_2)_m-$, and $(CH_2)_m-C\equiv C-(CH_2)_m-$, wherein H is O, S, or NH, n is an integer between 1 and 6, and m is an integer between 1 and 3.

Preferably, L can be selected from: phenyl, cyclohexyl, dioxolanyl, oxathiolanyl, and cyclopentyl.

In an further alternative of the invention, when R_1 is C_{1-16} alkyl, R_1 can be an aromatic or non aromatic ring optionally interrupted with one or more heteroatom, and optionally substituted with one or more heteroatom,
 5 hydroxy, halogen, C_{1-16} alkyl, C_{1-16} acyl, C_{6-12} aryl, nitro, or substituted or unsubstituted amino.

More preferably, R_1 can be OH, OCH_3 , SH or SCH_3 .

10 Alternatively, R_1 can be selected from the group consisting of: hydrogen, halogen, C_{1-6} alkyl, unsubstituted or substituted amino, OH, and OC_{1-6} alkyl, SH, or SC_{1-6} alkyl.

Preferably, R_1 can be chloro.

15


Alternatively, R_1 can be represented by formula NR^5R^6 wherein R^5 and R^6 are independently selected from the group consisting of hydrogen, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} acyl, substituted or unsubstituted amino, and C_{6-10} aryl.

20


Preferably, R_1 can be selected from the group consisting of:



25



, or



30

, wherein R_{20} is H or methyl.

Even more preferably, R_1 can be: $-N(CH_3)_2$.

Even more preferably, R_1 can be: $-NHNH_2$.

Even more preferably, R_1 can be: $-NHCH_3$,

5 Even more preferably, R_1 can be: $-NH_2$, and

Even more preferably, R_1 can be: $-N(NH_2)CH_3$.

Most preferably, R_1 can be $-N(CH_3)_2$.

10 In a further alternative embodiment of the invention, R_2 and R_3 can be independently selected from the group consisting of: Cl, Br, I, and F.

Preferably, R_2 and R_3 can be independently Cl, or Br.

15

More preferably, R_2 can be H, Cl, or NH_2 .

More preferably, R_3 can be H, Br, or SH, or SCH_3 .

20 Most preferably, the compound of the invention is represented by formula (I) wherein R_1 is $N(CH_3)_2$; R_2 and R_3 are both hydrogen; and R_4 is pentyloxycarbonyl-D-arginine, or pharmaceutically acceptable derivatives thereof.

25 Preferred compounds of the present invention are selected from:

Compound #III N-(6-Chloropurin-9-yl)-5-pentanol

Compound #V N-(6-N,N-Dimethylaminopurin-9-yl)-
pentanol

30 Compound #1 N,N-Dimethylaminopurinyl

Pentoxycarbonyl D-Arginine

Compound #2 N,N-Dimethylaminopurinyl

Pentoxycarbonyl L-Arginine

- Compound #3 N-Monomethylaminopuriny1
Pentoxycarbonyl D-Arginine
- Compound #3a N-(6-N-Methyl-Aminopurin-9-yl)-
pentanol
- 5 Compound #4 N-Monomethylaminopuriny1
Pentoxycarbonyl L-Arginine
- Compound #5 Aminopuriny1 Pentoxycarbonyl D-
Arginine
- Compound #5a N-(6-Aminopurin-9-Yl) 5-Pentanol
- 10 Compound #6 Aminopuriny1 Pentoxycarbonyl L-
Arginine
- Compound #7 Hydrazinopuriny1 Pentoxycarbonyl D-
Arginine
- Compound #7a N-(6-Hydrazinopurin-9-yl) 5-Pentanol
- 15 Compound #8 Hydrazinopuriny1 Pentoxycarbonyl L-
Arginine;
- Compound #9 Chloropuriny1 Pentoxycarbonyl D-
Arginine;
- Compound #10 Chloropuriny1 Pentoxycarbonyl L-
Arginine;
- 20 Compound #11 Hydroxypuriny1 Pentoxycarbonyl D-
Arginine;
- Compound #12 Mercaptopuriny1 Pentoxycarbonyl D-
Arginine;
- 25 Compound #13 Mercaptopuriny1 Pentoxycarbonyl L-
Arginine;
- Compound #14 N,N-Dimethylaminopuriny1
Pentoxycarbonyl Glycine;
- Compound #15 N,N-(6-Dimethylaminopurin-9-yl)-7'-
ethoxy-ethoxycarbonyl-D-arginine;
- 30 Compound #16 (2S,4S)-2-(N,N-dimethylaminopurin-9-
yl)-4-(methyloxycarbonyl-D-arginine)-1,3-dioxolane;
- Compound #17 N-(6-Dimethylamino-8-bromopuriny1-
Pentoxycarbonyl L-Arginine;

- Compound #18 N-(6-dimethylamino-8-bromopurin-9-yl)
7-pentoxycarbonyl-D-arginine;
- Compound #19 N-9-purinyl-5-pentanol;
- Compound #20 N-9-purinyl-7-pentyloxycarbonyl-D-
5 arginine;
- Compound #21 N-9-purinyl-7-pentyloxycarbonyl-L-
arginine;
- Compound #22 N,N-Dimethylaminopurinyl
Pentoxycarbonyl L-Valyl L-Prolyl L-Leucine;
- 10 Compound #23 N,N-Dimethylaminopurinyl
Pentoxycarbonyl L-Isoleucyl L-Prolyl L-Isoleucine;
- Compound #24 N-(6-Cyclopropylaminopurin-9-yl)-5-
pentanol;
- Compound #25 N-(6-cyclopropylaminopurin-9-yl)-7-
15 pentyloxycarbonyl-D-arginine;
- Compound #26 N-(6-cyclopropylaminopurin-9-yl)-7-
pentyloxycarbonyl-L-arginine;
- Compound #27 N-(6-Azetidinepurin-9-yl)-5-pentanol;
- Compound #28 N-(6-Azetidinepurin-9-yl)-7-
20 pentyloxycarbonyl-D-arginine;
- Compound #29 N-(6-Azetidinepurin-9-yl)-7-
pentyloxycarbonyl-L-arginine;
- Compound #30 trans-(N-6-chloropurin-9-yl)-4-methyl-
cyclohexyl-methanol;
- 25 Compound #31 trans-(N-6-dimethylaminopurin-9-yl)-4-
methyl-cyclohexyl-methanol;
- Compound #32 trans-(N-6-dimethylaminopurin-9-yl)-4-
methyl-cyclohexyl-methyloxycarbonyl-D-arginine;
- Compound #33 trans-(N-6-hydroxypurin-9-yl)-4-
30 methyl-cyclohexyl-methanol;
- Compound #34 trans-(N-6-methoxypurin-9-yl)-4-
methyl-cyclohexyl-methanol;
- Compound #35 cis-(N-6-dimethylaminopurin-9-yl)-4-
methyl-cyclohexyl-methanol;

- Compound #36 cis-(N-6-dimethylaminopurin-9-yl)-4-methyl-cyclohexyl-methyloxycarbonyl-D-arginine;
- Compound #37 N-(6-dimethylaminopurin-9-yl) 7-pentoxycarbonyl-D-citrulline;
- 5 Compound #38 N-(6-methylaziridinepurin-9-yl)-5-pentanol;
- Compound #39 racemic N-(6-methylaziridine purine-9-yl)-7-pentyloxycarbonyl-D-arginine;
- Compound #40 N,N-(6-Dimethylaminopuriny1-9-yl)-7-thioethoxy-ethoxycarbonyl-D-arginine;
- 10 Compound #41 Meta-(N-6-dimethylaminopuriny1-9-yl) methyl-benzyloxycarbonyl-D-arginine;
- Compound #42 5-(N-6-Dimethylaminopuriny1-9-yl)-3-pentynyl-1-oxycarbonylD-arginine;
- 15 Compound #43 Racemic N-[6-(1-methyl-2-acetoxy)-ethylaminopurin-9-yl]-5-pentanol;
- Compound #44 Racemic N-[6-(1-methyl-2-acetoxy), ethylaminopurin-9-yl]-7-pentyloxy-carbonyl-D-arginine;
- 20 Compound #45 N-(2,6-Dichloropurin-9-yl)-5-pentanol;
- Compound #46 N-(2,6-Dichloropurin-9-yl)-7-pentyloxycarbonyl-D-arginine;
- Compound #47 N-(2,6-Dichloropurin-9-yl)-7-pentyloxycarbonyl-L-arginine;
- 25 Compound #48 N-(2-Amino, 6-N, N-Dimethylaminopurin-9-yl)-5-pentanol;
- Compound #49 N-(6-dimethylamino-8-methylthiopurin-9-yl) 5-pentanol;
- Compound #50 N-(6-dimethylamino-8-methylthiopurin-9-yl) 7-pentoxycarbonyl-D-arginine;
- 30 Compound #51 N-(6-methoxypurin-9-yl) 5-pentanol;
- Compound #52 N-(6-methoxypurin-9-yl) 7-pentoxycarbonyl-D-arginine;

- Compound #53 N-(2-chloro-6-methoxypurin-9-yl)-7-pentoxycarbonyl-D-arginine;
- Compound #54 N-(6-dimethylaminopurin-9-yl) 7-pentoxycarbonyl-D-ornithine;
- 5 Compound #55 N-(6-dimethylaminopurin-9-yl) 7-pentoxycarbonyl-L-ornithine;
- Compound #56 N-(6-dimethylaminopurin-9-yl) 7-pentoxycarbonyl-L-valine;
- Compound #57 N-(6-dimethylamino-9-yl) 7-pentoxycarbonyl-D-valine;
- 10 Compound #58 N(N,N-dimethylaminopurin-9-yl)-7-pentoxycarbonylethylamine hydrochloride;
- Compound #59 N-(6-Mercaptopurin-9-yl)-pentanol;
- Compound #60 N-(6,-N-Methylthiopurin-9-yl)-pentanol;
- 15 Compound #61 N-(6-chloropurin-9-yl) 4-butanol;
- Compound #62 N-(6-dimethylaminopurin-9-yl) 4-butanol;
- Compound #63 N-(6-dimethylaminopurin-9-yl)-6-butoxycarbonyl-D-arginine;
- 20 Compound #64 N-(6-dimethylaminopurin-9-yl)-6-butoxycarbonyl-L-arginine;
- Compound #65 N-(6-chloropurin-9-yl)-6-hexanol;
- Compound #66 N-(6-N,N-dimethylaminopurin-9-yl)-6-hexanol;
- 25 Compound #67 N-(6-N,N-dimethylaminopurin-9-yl)-8-hexyloxycarbonyl-D-arginine;
- Compound #68 N(6-N,N-dimethylaminopurine-9-yl)-8-hexyloxycarbonyl-L-arginine;
- 30 Compound #69 cis-(N-6-hydroxypurin-9-yl)-4-methylcyclohexyl-methanol;
- Compound #70 cis-(N-6-hydroxypurin-9-yl)-4-methylcyclohexyl-methyloxycarbonyl-D-arginine;

- Compound #71 trans-(N-6-hydroxypurin-9-yl)-4-methyl-cyclohexyl-methyloxycarbonyl-D-arginine;
- Compound #72 N-(6-N,N dimethylaminopurin-9-yl)-5-pentylamine hydrochloride salt;
- 5 Compound #73 N-(6-methylaziridinepurin-9-yl)-7-pentyloxycarbonyl-L-arginine;
- Compound #74 (2S,4S)-2-(N,N-Dimethylaminopurin-9-yl)-4-hydroxymethyl-1,3-dioxolane;
- Compound #75 (1S,3R) and (1R,3S)-1-(N-6-Dimethylaminopurin-9-yl)methyl-3-cyclopentane
10 methanol;
- Compound #76 (1S,3R) and (1R,3S)-1-(N-6-Dimethylaminopurin-9-yl)methyl-3-(methyloxycarbonyl-D-arginine)cyclopentane;
- 15 Compound #77 N,N-(6-Dimethylaminopurin-9-yl)-7-ethylaminoethanol;
- Compound #78 N,N-(6-Dimethylaminopurin-9-yl)-7-ethylaminoethoxycarbonyl-D-arginine;
- Compound #79 N,N-(6-Dimethylaminopurin-9-yl)-7-ethylaminoethoxycarbonyl-L-arginine;
- 20 Compound #80 5-(N-6-Dimethylaminopurin-9-yl)-3-pentyn-1-ol;
- Compound #81 5-(N-6-Dimethylaminopurin-9-yl)-3-pentynyl-1-oxycarbonyl-L-arginine;
- 25 Compound #82 N,N-(6-Dimethylaminopurin-9-yl)-7-thioethoxy-ethanol;
- Compound #83 N,N-(6-Dimethylaminopurin-9-yl)-7-thioethoxy-ethoxycarbonyl-L-arginine;
- Compound #84 (2S,4S) and (2R,4R)-2-(N,N-Dimethylaminopurin-9-yl)-4-(methoxycarbonyl-D-arginine)-1,3-oxathiolane;
- 30 Compound #85 N,N-(6-Dimethylaminopurin-9-yl)-7-ethoxy-ethoxyethanol;

- Compound #86 N,N-(6-Dimethylaminopurin-9-yl)-7-ethoxy-ethoxycarbonyl-D-arginine;
 Compound #87 N,N-(6-Dimethylaminopurin-9-yl)-7-ethoxy-ethoxycarbonyl-L-arginine; and
 5 Compound #88 N-(6-Dimethylamino-8-bromopurin-9-yl)-5-pentanol.

More preferably, the compound of the present invention is selected from:

- 10 Compound #III N-(6-Chloropurin-9-yl)-5-pentanol
 Compound #V N-(6-N,N-Dimethylaminopurin-9-yl)-pentanol
 Compound #1 N,N-Dimethylaminopurinyl Pentoxycarbonyl D-Arginine
 15 Compound #2 N,N-Dimethylaminopurinyl Pentoxycarbonyl L-Arginine
 Compound #3 N-Monomethylaminopurinyl Pentoxycarbonyl D-Arginine
 Compound #3a N-(6-N-Methyl-Aminopurin-9-yl)-pentanol
 20 Compound #5 Aminopurinyl Pentoxycarbonyl D-Arginine
 Compound #5a N-(6-Aminopurin-9-Yl) 5-Pentanol
 Compound #6 Aminopurinyl Pentoxycarbonyl L-Arginine
 25 Compound #7 Hydrazinopurinyl Pentoxycarbonyl D-Arginine
 Compound #7a N-(6-Hydrazinopurin-9-yl) 5-Pentanol
 Compound #8 Hydrazinopurinyl Pentoxycarbonyl L-Arginine;
 30 Compound #11 Hydroxypurinyl Pentoxycarbonyl D-Arginine;
 Compound #19 N-9-purinyl-5-pentanol;

- Compound #20 N-9-purinyl-7-pentyloxycarbonyl-D-
 arginine;
Compound #51 N-(6-methoxypurin-9-yl) 5-pentanol;
Compound #59 N-(6-Mercaptopurin-9-yl)-pentanol; and
5 Compound #60 N-(6,-N-Methylthiopurin-9-yl)-
 pentanol.

Most preferably, the compound of the present invention is
N,N-(6-dimethylaminopurin-9-yl)-7-pentoxycarbonyl-D-
10 arginine .

The following abbreviations and definitions are used
herein:

- PHA - phytohemagglutinin
15 ConA - concanavalin A
CY - cyclophosphamide
PWM - pokeweed mitogen
LPS - lipopolysaccharide
DEAD - diethylazodicarboxylate
20 PBS - phosphate buffered saline
TBDPSCl - tert-butyldiphenylsilyl chloride
CTX - Cytosan

The term "conservative substitution" as employed herein
25 refers to modifications and substitutions of amino acids
which are conservative ones, i.e. those having a minimal
influence on the secondary structure and hydropathic
nature of the amino acid or peptide. These include
substitutions such as those described by Dayhoff in the
30 Atlas of Protein Sequence and Structure 5, 1978, and by
Argos in EMBO J., 8, 779-785, 1989. For example, amino
acids belonging to the following groups represent
conservative changes: ala, pro, gly, glu, asp, gln, asn,
ser, thr; cys, ser, tyr, thr; val, ile, leu, met, ala,

phe; lys, arg, his; and phe, tyr, trp, his. The preferred substitutions also include substitutions of D-isomers for the corresponding L-amino acids.

5 It has been surprisingly discovered that contrary to the well-established prior art, hypoxanthine or other naturally occurring purine bases such as adenine or guanine need not be used in the design of an immunostimulant of the type similar to ST 789. In fact
10 replacement of hypoxanthine with a 6-substituted purine base that does not occur in biological systems can provide an equal or even greater degree of immunostimulation. Further, it has been surprisingly discovered that the amino acid need not be of the (natural) L-configuration.

15

It will be recognized that the designation of a naturally occurring amino acid does not preclude the use of racemic mixtures or D-enantiomers and in one aspect of the invention, it is especially preferred to use amino acids
20 in the D-configuration.

It has surprisingly been discovered that the compounds of the invention possess *in vitro* and *in vivo* activity to increase the number of cytotoxic T lymphocytes in the
25 mammal being treated.

It has further been discovered that the compounds of the present invention are surprisingly active against tumor growth. The compounds of this invention represents a non-
30 toxic substitute to levamisole in the treatment of malignant melanoma.

When tested in mice against a control group, the compounds of the present invention significantly inhibit tumor


growth when used in combination with cyclophosphamide or 5-fluorouracil, particularly against mammary and colon carcinoma respectively.

- 5 The compounds of the present invention may be prepared by the use of synthetic methods well known in the art. Thus, for example, it is possible to follow the synthetic procedure described by R. Stradi et al. in *Il Farmaco*, 45, 39-47, 1990, with the provision that the chlorine atom
- 10 from the chloropurine intermediate must be displaced by an appropriate substituent other than hydroxyl. However, it is preferred to carry out a modification of this synthetic procedure, as outlined in the following examples, wherein the purine ring is already constructed by use of 6-
- 15 chloropurine as a starting material. This avoids the need to build the purine ring and thereby provides a more efficient and higher yield preparation of the desired immunostimulant. This preferred synthetic pathway is outlined in Scheme 1.

20

- In Scheme 1, R_4' which is $(CH_2)_{1-8}-O-CO-X^{12}$ as defined above, is reacted with a protecting group in the presence of a base such as NaH/THF to produce compound V. L represents a leaving group well known to those skilled in
- 25 the art. Any suitable leaving group can be used. Pg is a protecting group well known in the art. Any suitable protecting group can be used.

SCHEME 1



Compound V is coupled with compound IV, for example, in
 5 the presence of $DEAD$ and PPh_3/THF to yield compound III.
 Compound IV can be prepared using known techniques in the
 art. As well, R_1 can be added before this step or at a
 later step using techniques well known in the art.

Compound III is deprotected by using methodology well known to those skilled in the art, for example, with $(C_4H_9)_4NF/THF$ and $AcOH$ for a OTBDPS protecting group, to yield compound II. This compound is further optionally
5 reacted with an amino acid or a peptide group of 1-8 amino acids in length, for example, in the presence of $ClCOCl/THF$ and H_2O . The resultant compound is a compound of formula I.

10 Those skilled in the art will appreciate that compounds of formula 1 wherein R_4 is not an amino acid or peptide chain can be synthesized by utilizing steps 1 to 3 without the addition step 4.

15 It will be appreciated by those skilled in the art that the compounds of the present invention include all pharmaceutically acceptable derivatives and analogues thereof, as well as all isomers and enantiomers.

20 Another aspect of the invention is the use of the compounds of formula I or pharmaceutical preparations for the manufacture of a medicament.

Another aspect of the invention is the method of treatment
25 of a mammal, preferably a human, comprising the step of administering a compound of formula I, a pharmaceutical composition, or a pharmaceutically acceptable derivative thereof for the treatment of immune deficiency or control of tumor growth.

30

It will be appreciated by those skilled in the art that the reference herein to treatment extends to prophylaxis as well as treatment of established infections or symptoms and therefore includes control of tumor outgrowth.

It will be further appreciated that the amount of a compound of the invention required for use in treatment will vary not only with the particular compound selected
5 but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or veterinarian.

10 In general, however, a suitable dose will be in the range from about 0.1 to about 250 mg/kg of body weight per day. Preferably, doses will range from about 1 to about 100 mg/kg/day. More preferably between about 2 to about 20 mg/kg. Most preferably about 2.5 mg/kg. Still, most
15 preferably about 450 mg/m².

The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example as two, three, four or more sub-
20 doses per day.

The compound is conveniently administered in unit dosage form; for example containing 10 to 1500 mg, conveniently 20 to 1000 mg, most conveniently 50 to 700 mg of active
25 ingredient per unit dosage form.

Ideally the active ingredient should be administered to achieve peak plasma concentrations of the active compound. This may be achieved, for example, by the intravenous
30 injection of a solution of the active ingredient, optionally in saline, or administered as a bolus. Desirable blood levels may be maintained by a continuous infusion or by intermittent infusions.

While it is possible that, for use in therapy, a compound of the invention may be administered as the raw chemical, it is preferable to present the active ingredient as a pharmaceutical formulation.

5

The invention thus further provides a pharmaceutical formulation comprising a compound of formula (I) or a pharmaceutically acceptable derivative thereof together with one or more pharmaceutically acceptable carriers thereof and, optionally, other therapeutic ingredients. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

15 Pharmaceutical formulations include those suitable for topical, oral, rectal, nasal, or parenteral (including intramuscular, sub-cutaneous and intravenous) administration or in a form suitable for administration by inhalation or insufflation. The formulations may, where
20 appropriate, be conveniently presented in discrete dosage units and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association the active compound with liquid carriers or finely divided solid carriers or both and
25 then, if necessary, shaping the product into the desired formulation.

For topical administration to the epidermis, the compounds according to the invention may be formulated as ointments,
30 creams or lotions, or as a transdermal patch. Such transdermal patches may contain penetration enhancers such as linalool, carvacrol, thymol, citral, menthol and t-anethole. Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition
35 of suitable thickening and/or gelling agents. Lotions may

be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or colouring agents.

5

Pharmaceutical formulations suitable for oral administration may conveniently be presented as discrete units such as capsules, cachets, or tablets. Each pressurized packs may comprise a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide, or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount.

15

Alternatively, for administration by inhalation or insufflation, the compounds according to the invention may take the form of a dry powder composition, for example a powder mix of the compound and a suitable powder base such as lactose or starch. The powder composition may be presented in unit dosage form in, for example, capsules or cartridges or, e.g., gelatin or blister packs from which the powder may be administered with the aid of an inhalator or insufflator.

25

When desired, the above described formulations adapted to give sustained release of the active ingredient may be employed.

30 The compounds of the invention may also be used in combination with other therapeutic agents, for example, other immunomodulators or tumor control agents.

The invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a

35

physiologically acceptable derivative thereof together with another therapeutically active agent.

Such therapeutically active agents include cytotoxic
5 agents used to treat tumors. Such cytotoxic agents include cyclophosphamide, or 5-fluorouracil (5-FU).

Preferably, cyclophosphamide doses used in the treatment of tumors range from about 10 to 1000 mg/m².
10 Morepreferably, from about 100 to about 500 mg/m². Most preferably, about 350 mg/m²/day.

Also preferably, 5-fluorouracil doses used in the treatment of tumors ranges from about 0.1 to about 250
15 mg/kg. Preferably, between about 1 to about 50 mg/kg. More preferably, between about 5 to about 20 mg/kg. Most preferably, at about 12 mg/kg (500 mg/m²).

As will be recognized by people skilled in the art of
20 cancer therapy, such doses will vary with the type of malignancy being treated, the stage of the disease, the responsiveness of the tumor, etc..

The combinations referred to above may conveniently be
25 presented for use in the form of a pharmaceutical composition and thus pharmaceutical composition comprising a combination as defined above together with a pharmaceutically acceptable carrier thereof comprise a further aspect of the invention.

30

The individual components of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations.

When the compound of formula (I) or a pharmaceutically acceptable derivative thereof is used in combination with a second therapeutic agent, the dose of each compound may be either the same or differ from that when the compound
5 is used alone. Appropriate doses will be readily appreciated by those skilled in the art.

In a further embodiment of the invention, there is provided a method of treatment of immune deficiencies or
10 for the control of tumor growth comprising the step of administering a pharmaceutically acceptable amount of a compound of the invention.

Preferably, such tumors include malignant melanoma,
15 mammary and colon carcinoma.

More preferably, there is provided a method for the treatment of mammary carcinoma comprising the step of administering a pharmaceutically acceptable amount of a
20 compound of the invention, in combination with cyclophosphamide.


Most preferably, there is provided a method for the treatment of colon carcinoma comprising the step of
25 administering a pharmaceutically acceptable amount of a compound of the invention, in combination with 5-fluorouracil.

The invention will be further described by the following
30 examples which are not intended to limit the invention in any way. All temperatures are in degrees Celsius.

EXAMPLES

The compounds of formula I were synthesized and tested for immunological activity using the procedures outlined below.

5 Example 1a Synthesis of N,N-Dimethylaminopurinyll
Pentoxycarbonyl D-Arginine -
Compound #1



Step 1:

a) Synthesis of protected 1,5 - pentanediol

5 4.0 g., 36.3 mmole of pentanediol was dissolved in 75 ml dry tetrahydrofuran and stirred under argon flow. Sodium hydride (1.4 g., 57.8 mmole) was added and the suspension was stirred for 30 minutes, and then tert-butylldiphenylsilyl chloride (8.0 ml, 30.8 mmole) dissolved in 25 ml dry tetrahydrofuran was added
10 dropwise to the diol solution. The reaction was stirred at ambient temperature and under argon overnight. The suspension was then poured onto 100 ml ether. The ethereal suspension was washed with 10% potassium carbonate (100 ml), brine (100ml) and dried
15 with magnesium sulfate. Removal of the solvent in vacuo gave 10.3 g., 30.1 mmole of product in 98% yield which was used without further purification.

b) Coupling of Compound I with 6-chloropurine

20 To a stirred solution of triphenylphosphine (4.7 g., 17.9 mmole), and 6-chloropurine (2.3g., 15.1 mmole) in 100 ml dry tetrahydrofuran, under argon flow, was added diethylazodicarboxylate (DEAD, 2.8 ml, 17.9
25 mmole). After 10 minutes, compound I (4.7 g., 13.7 mmole) dissolved in 20 ml dry tetrahydrofuran was added dropwise to the reaction, which was then stirred at ambient temperature and under argon overnight. The solvent was removed in vacuo, and the
30 crude product was purified by flash silica gel chromatography using 30% ethyl acetate-hexane as eluent (R = 0.30). The product, compound II, 3.7 g., 7.6 mmole, was obtained in 55% yield as a colorless oil.

35

Step 2: Removal of silyl protecting group

2.3g, 4.4 mmole of compound II was dissolved in 40 ml dry tetrahydrofuran and stirred under argon flow.
5 Tetrabutylammonium fluoride (5.3 ml, 5.1 mmole) was added and the reaction was stirred at ambient temperature and under argon overnight. To the solution was added glacial acetic acid (90.31 ml, 5.3 mmole) and the solvent was removed *in vacuo*. The crude product
10 was purified by flash silica gel chromatography using 10% methanol-ethyl acetate as eluent ($R_f = 0.20$). The product was taken up in minimal methylene chloride and filtered through celite to remove silica. The solvent was removed *in vacuo*, and the product dried, giving
15 compound III, 1.0 g, 4.2 mmole, in 95% yield.

Step 3: Coupling of compound III with D-arginine

1.0g., 4.2 mmole of 6-chloropurinyl pentanol, compound
20 III, was dissolved in 75 ml dry tetrahydrofuran and stirred under argon flow. Toluene phosgene (4.4 ml., 8.3 mmole) was added and the reaction was monitored by TLC (developed in methanol) and continued until the intermediate chloroformate was the predominant product
25 (6-10 hours). The solvent was removed *in vacuo*, and the residue was taken up in 50 ml. dry tetrahydrofuran. D-arginine (0.94 g., 5.4 mmole), dissolved in 5 ml. water, was added to the chloroformate suspension. Another 5 ml. aliquot of water was used to rinse the
30 beaker which contained the arginine solution, and then added to the reaction. The reaction was stirred overnight at ambient temperature, and then extracted with toluene (60 ml.). The toluene was back extracted with water (60 ml.) and the combined aqueous portions
35 were brought to slightly alkaline pH by the addition of 5% sodium bicarbonate. Water was removed *in vacuo* and the residue was dissolved in methanol (10 ml.). After filtration, the methanolic solution was added dropwise


to 500 ml vigorously stirred acetone. The precipitate was collected by filtration and washed several times with acetone. The filtrate contained unreacted III. The precipitate was dried, and then dissolved in water (50 ml.). to the aqueous solution was added dimethylamine (40% aqueous solution, 5.0 ml, 40 mmole) and the reaction was stirred for 3 hours at ambient temperature. The solvent was removed in vacuo and the crude product was purified by flash silica gel chromatography, using methanol as eluent ($R_f = 0.25$). The combined product fractions were reduced in volume (approximately 5 ml) and stored at 4°C for 2 hours. The solution was centrifuged for 10 minutes (375 x g) to remove silica, and the supernatant was added dropwise to 500 ml vigorously stirred ether. The precipitate was collected by filtration and dried to give N,N-dimethylaminopurinyI pentoxycarbonyl D-arginine, compound #1, 0.79 g., 1.8 mmole in 43% yield.

mp (softens 119°C) = 123° - 125°C

Rf silica (methanol) = 0.30

^1H NMR (DMSO - d_6 , 300 MHz, δ in ppm); 9.40 (1H, br, s, COOH); 8.20 (1H, s, purine); 8.15 (1H, s, purine); 8.0 - 7.3 (4H, b, guanidine); 6.33 (1H, d, NH); 4.13 (2H, t, N-CH₂); 3.86 (2H, t, O-CH₂); 3.63 (1H, m, C ^{α} H); 3.36 (6H, s, b, N-(CH₃)₂); 3.02 (2H, b, C ^{β} H); 1.8-1.2 (10H, m, C ^{β} H, C ^{γ} H, -(CH₂)₃ -). MS (high-resolution FAB, glycerol); m/e, 450.25780; calculated for M+H⁺, (C₁₉H₃₂O₄N₉), 450.25773.

Example 1b Alternative Synthesis of N,N-Dimethylaminopurinyll
Pentoxycarbonyl D-Arginine - **Compound #1**



5

Step 1: A modified synthesis of compound #1 was undertaken by reaction of protected 6-chloropurinyll pentanol, compound II (prepared as described in example 1a) with aqueous dimethylamine, followed by deprotection to yield compound V, and coupling with D-arginine (the coupling reaction is as described in example 1a) to

10

give the product. The spectral and chromatographic properties were identical to the product obtained from the synthesis described in example 1a.

5 A typical example of the reaction of protected 6-chloropurinyl pentanol, compound II, with dimethylamine is as follows; to 0.13 g., 0.26 mmole of compound II dissolved in 20 ml tetrahydrofuran was added dimethylamine (40% aqueous solution, 0.5 ml, 10:0
10 mmole). The reaction was stirred for 18 hours at ambient temperature, and the solvent was removed in vacuo. the crude product was purified by flash silica gel chromatography, using 50% ethyl acetate-hexane as eluent (R_f = 0.27). The product compound V, 0.12 g.
15 0.30 mmole, was obtained in 94% yield.

Example 2 Synthesis of N,N-Dimethylaminopurinyl Pentoxycarbonyl
L-Arginine - Compound #2

20 The L-enantiomer of compound #1, compound #2, was synthesized as described above in example 1b to give 50 mg. of product as a white solid.
mp (softens 118°C) = 123° - 125°C.
Spectral properties were identical with compound #1 .

25

Example 3 Synthesis of N-Monomethylaminopurinyl Pentoxycarbonyl
D-Arginine - Compound #3

Compound #3 was synthesized as described above in example 1b,
30 except that dimethylamine was replaced with methylamine (40% aqueous solution) to give 6-methylaminopurinyl pentanol compound #3a. This was then coupled with D-arginine, as described in example 1a to give 32 mg. of product.
mp (softens at 127°C) = 133°C.
35 R_f silica (methanol) = 0.20
 ^1H NMR (DMSO- d_6 , 300 MHz, δ in ppm);

- 9.30 (1H, b, COOH), 8.21 (1H, s, purine); 8.13 (1H, s, purine); 7.8-7.2 (4H, b, guanidine); 6.29 (1H, d, NH); 4.13 (2H, t, N-CH₂); 3.86 (2H, t, O-CH₂); 3.61 (1H, m, C^αH); 3.17 (1H, m, CH₃-NH); 3.02 (3H, b, HN-CH₃); 2.97 (2H, b, C^δH); 1.9-1.2 (10H, m, C^βH, C^γH, - (CH₂)₃-).

Example 4 Synthesis of N-Monomethylaminopurinyll Pentoxycarbonyl L-Arginine - Compound #4

- 10 The L-enantiomer of compound #3 and compound #4, was synthesized as described above in example 3 to give 44 mg. of product as a white solid.
mp (softens at 123°C) - 132° - 134°C.
Rf silica (methanol) = 0.20.
- 15 Spectral properties were identical with compound #3.

Example 5 Synthesis of Aminopurinyll Pentoxycarbonyl D-Arginine - Compound #5

- 20 Compound #5 was synthesized as described above in example 1b except that protected 6-chloropurinyll pentanol, compound II, was reacted with ammonia gas instead of dimethylamine. The 6-aminopurinyll (adenine) product was thus deprotected to give the alcohol compound #5a. This was then coupled with D-arginine to
- 25 give 260 mg. of product as a white solid. A typical example of the reaction of compound II with ammonia is as follows; 0.42g, 0.88 mmole of compound II was dissolved in 75 ml absolute ethanol, and the solution was placed on an ice bath. Ammonia gas was bubbled through the chilled solution for 10 minutes, and
- 30 the saturated solution was transferred to a bomb (150 ml cylinder). Ammonia gas was bubbled through the solution for another minute, the bomb sealed, and the bomb was heated overnight in a 120°C oil bath. Solvent was removed in vacuo, yielding 0.40 g., 0.88 mmole of product in 95% yield. This
- 35 product was used without further purification.
Characteristics of compound #5;
mp (softens 143°C) - 150°C.

Rf silica (methanol) = 0.20

¹HNMR (DMSO-d₆, 300 MHz, δ in ppm); 9.40 (1H, b, COOH); 8.14 (1H, s, purine); 8.13 (1H, s, purine); 8.0 - 7.0 (6H, m, guanidine, -NH₂); 6.36 (1H, b, NH); 4.13 (2H, t, N-CH₂); 3.87 (2H, t, O-CH₂); 3.65 (1H, m, C^αH); 3.03 (2H, b, C^δH); 1.9-1.2 (10H, m, C^βH, C^γH, - (CH₂)₃-).

Example 6 Synthesis of Aminopurinylyl Pentoxycarbonyl L-Arginine
- Compound #6

10

The L-enantiomer of compound #5, compound #6, was synthesized as described above in example 5 to give 93 mg of product as a white solid.

mp (softens at 143°C = 153° - 155°C.

15 Rf silica (methanol) = 0.22

Spectral properties were identical with compound #5.

Example 7 Synthesis of Hydrazinopurinylyl Pentoxycarbonyl D-Arginine - Compound #7

20

Compound #7 was synthesized as described above in example 1a, except that dimethylamine was replaced with hydrazine from the corresponding alcohol compound #7a. Thus, in a typical example, 50 mg, 0.11 mmole of 6-chloropurinylyl pentoxycarbonyl D-arginine, dissolved in 5 ml 95% ethanol, was reacted with
25 hydrazine hydrate (12 µl, 0.40 mmole) at ambient temperature overnight. The reaction was then slowly cooled to 0°C for 3 hours, and the resulting crystals were collected by filtration, and washed with cold ethanol. The white solid product, 32 mg.,
30 0.07 mmole, was obtained in 65% yield.

mp(softens 130°C) = 134°C

Rf silica (methanol) = 0.27

¹HNMR (DMSO-d₆, 300 MHz, δ in ppm); 9.20 (1H, b, COOH); 8.23 (1H, s, purine); 8.14 (1H, s, purine); 7.4 (3H, b, guanidine);
35 6.6 (2H, b, NH₂); 6.43 (1H, d, NH); 4.14 (2H, t, N-CH₂); 3.87

(2H, t, O-CH₂); 3.64 (1H, m, C^αH); 3.04 (2H, b, C^δH); 1.8-1.3 (10H, m, C^βH, C^γH, - (CH₂)₃-).

Example 8 Synthesis of Hydrazinopurinyl Pentoxycarbonyl L-Arginine - **Compound #8**

The L-enantiomer of compound #7, compound #8, was synthesized as described in example 7 to give 40 mg of product as a white solid.

mp (softens at 130°C = 134°C.

Rf silica (methanol) = 0.27

Spectral properties were identical with compound #7.

Example 9 Synthesis of Chloropurinyl Pentoxycarbonyl D-Arginine - **Compound #9**

Compound #9 was synthesized by the coupling reaction of 6-chloropurinyl pentanol, compound III, with D-arginine, as described in example 1a (with omission of the addition of dimethylamine after the coupling reaction). This gave 622 mg of product as a white solid.

mp (softens 137°C) = 145° - 148°C.

Rf silica (methanol) = 0.35

¹HNMR (DMSO-d₆, 300 MHz, δ in ppm); 9.15 (1H, b, COOH); 8.78 (1H, s, purine); 8.74 (1H, s, purine); 7.8-7.2 (4H, b, guanidine); 6.33 (1H, d, NH); 4.29 (2H, t, N-CH₂); 3.88 (2H, t, O-CH₂); 3.64 (1H, m, C^αH); 3.04 (2H, b, C^δH); 1.95-1.20 (10H, m, C^βH, C^γH, - (CH₂)₃-).

Example 10 Synthesis of Chloropurinyl Pentoxycarbonyl L-Arginine - **Compound #10**

The L-enantiomer of compound #9, compound #10, was synthesized as described above in example 9 to give 65 mg of product as a white solid.

mp (softens at 137°C) = 143-146°C.

Rf silica (methanol) = 0.26

Spectral properties were identical with compound #9.

Example 11 Synthesis of Hydroxypurinyl Pentoxycarbonyl D-Arginine - Compound #11

5 Compound #11 was synthesized as described in example 9 above except that the 6-chloropurinyl pentanol intermediate, compound III, was first subjected to base catalyzed hydrolysis to yield 6-hydroxypurinyl (hypoxanthine) pentanol compound #11a prior to
10 coupling with D-arginine. Thus, in a typical example, 398 mg, 1.7 mmole of compound III was dissolved in 25 ml of water. Sodium hydroxide (1.0 M, 3.4 ml) was added, and the reaction was refluxed for 90 minutes. Upon cooling, the reaction was acidified (5% hydrochloric acid), the solvent removed in vacuo,
15 and the crude product purified by flash silica gel chromatography using 30% methanol-ethyl acetate as eluent ($R_f = 0.32$). The product, compound #11a, 290 mg, 1.3 mmole, was obtained in 79% yield as a white solid. Subsequent coupling with D-arginine gave 148 mg of compound #11 as a white solid.
20 mp(softens 163°C) = 182°C.
 R_f silica (methanol) = 0.22
 $^1\text{H NMR}$ (DMSO- d_6 , 300 MHz, δ in ppm): 9.28 (1H, b, COOH); 8.10 (1H, s, purine); 8.04 (1H, s, purine); 7.8-7.2 (4H, b, guanidine); 6.38 (1H, d, NH); 4.32 (1H, b, OH); 4.13 (2H, t, N-CH₂);
25 3.87 (2H, t, O-CH₂); 3.61 (1H, m, C ^{α} H); 3.04 (2H, b, C ^{δ} H); 1.8-1.1 (10H, m, C ^{β} H, C ^{γ} H, - (CH₂)₃-).

Example 12 Synthesis of Mercaptopurinyl Pentoxycarbonyl D-Arginine - Compound #12

30 Compound #12 was synthesized as described in example 1a, except that dimethylamine was replaced with thiourea. Thus, in a typical example, 80 mg, 0.18 mmole of 6-chloropurinyl pentoxycarbonyl D-arginine, dissolved in 5 ml absolute ethanol
35 was reacted with thiourea, 16 mg, 0.21 mmole, under reflux for 5 hours. The reaction was then stored at 0°C overnight and the resulting crystals were filtered and washed with cold absolute

ethanol. The product was recrystallized from absolute ethanol to give a white solid, 48 mg, 0.11 mmole in 61% yield.

mp(softens 180°C) = 200°C.

Rf silica (methanol) = 0.50

- 5 ¹HNMR (DMSO-d₆, 300 MHz, δ in ppm); 9.15 (1H, b, COOH); 8.29 (1H, s, purine); 8.18 (1H, s, purine); 7.5-7.3 (4H, b, guanidine); 6.39 (1H, d, NH); 4.13 (2H, t, N-CH₂); 3.87 (2H, t, O-CH₂); 3.65 (1H, m, C^αH); 3.04 (2H, b, C^δH); 1.90-1.23 (10H, m, C^βH, C^γH, - (CH₂)₃-).

10

Example 13 Synthesis of Mercaptopurinyll Pentoxycarbonyl L-Arginine - Compound #13

- 15 The L-enantiomer of compound #12, compound #13, was synthesized as described in example 12 to give 42 mg of product as a white solid.

mp (softens at 180°C = 200°C.

Rf silica (methanol) = 0.50

Spectral properties were identical with compound #12 .

20

Example 14 Synthesis of N,N-Dimethylaminopurinyll Pentoxycarbonyl Glycine - Compound #14

- 25 Compound #14 was synthesized as described above in example 1b except that the coupling reaction was undertaken on smaller scale, with glycine, 68 mg, 0.91 mmole, instead of arginine and the free base of glycine was generated in situ by the addition of 3 equivalents of sodium carbonate (relative to the alcohol). The crude product was purified by flash silica gel chromatography, using 50% methanol-ethyl acetate as eluent (Rf = 0.35). Silica was removed by dissolving the product in methylene chloride, followed by filtration. Removal of solvent in vacuo gave 30 mg of product as a white solid.

mp(softens 100°C) = 126°C.

- 35 Rf silica (1:1 methanol-ethyl acetate) = 0.35

¹HNMR (DMSO-d₆, 300 MHz, δ in ppm); 8.20 (s, 1H, purine); 8.16 (s, 1H, purine); 6.05 (1H, t, NH); 4.14 (2H, t, N-CH₂); 3.86

(2H, t, O-CH₂); 3.33 (6H, s, b, N-(CH₃)₂); 3.18 (2H, d, C^aH₂);
1.80 (2H, m, CH₂); 1.55 (2H, m, CH₂); 1.26 (2H, m, CH₂);

Example 15 N,N-(6-Dimethylaminopurin-9-yl)-7'-ethoxy-
ethoxycarbonyl-D-arginine - **Compound #15**

Step 1: N,N-(6-Dimethylaminopurin-9-yl)-5-ethoxyethoxy-t-
butyldiphenylsilane

10 To a solution of alcohol (0.201 g, 1 eq) in anh. THF
(2.9 ml), at room temperature, under argon, were added
successively 6-chloropurine (90 mg, 0.58 mmol), Ph₃P
(0.199 g, 1.3 eq) and DEAD (0.12 ml, 1.3 eq). The
15 yellow solution was stirred at room temperature for 15
hours. The THF was evaporated and the residue was
chromatographed (6:4, Hexanes/EtOAc) to give a mixture
of (EtO₂CNH)₂ and the coupled purine. To a solution of
this mixture in THF (6 ml), at room temperature, was
20 added 40% Me₂NH/H₂O (0.70 ml, 10 eq). The solution was
stirred at room temperature for 45 minutes and was then
poured in sat. aq. NaHCO₃/CH₂Cl₂. The phases were
separated and the aqueous phase was extracted with
CH₂Cl₂ (2x). The combined organic extracts were dried
25 over MgSO₄, the solids filtered and the solvents
evaporated. The residue was purified by flash
chromatography (silica gel, 2:8 Hex/AcOEt) to give 0.16
g (55%) of the coupled dimethyl amino purine.

Step 2: N,N-(6-Dimethylaminopurin-9-yl)-5-ethoxyethanol -
30 compound #85

To a solution of the silane (0.16 g, 0.32 mmol) in anh.
THF (3.2 ml), at room temperature, under argon, was
added nBu₄NF 1.0 M/THF (0.32 ml, 1.1 eq). The solution
35 was stirred at room temperature for 3 hours and the
solvent was evaporated in vacuo. The residue was
immediately purified by flash chromatography (silica

gel, 4:1 AcOEt/MeOH) to give 72 mg (89%) of the alcohol compound #85 as a clear oil.

5 ^1H NMR (CDCl_3): δ 8.29 (s, 1H, purine), 7.80 (s, 1H, purine), 4.33 (t, 2H, CH_2), 3.82 (t, 2H, CH_2), 3.68 (t, 2H, CH_2), 3.55 (t, 2H, CH_2), 3.50 (m, 6H, $\text{N}(\text{CH}_3)_2$).


10 **Step 3: N,N-(6-Dimethylaminopurin-9-yl)-7-ethoxyethoxycarbonyl-D-arginine - Compound #15**

To a solution of the alcohol, compound #85 (72 mg, 0.29 mmol) in anh. THF (4.8 ml), at room temperature, under argon, was added COCl_2 /Toluene 1.93 M (0.30 ml, 2 eq) and the solution was stirred at room temperature for 5 hours. The THF was evaporated in vacuo and the residue was redissolved in THF (3.6 ml). To this solution was added a solution of D-arginine in water (65 mg, 1.3 eq/0.5 ml H_2O). The flask containing the D-arginine solution was rinsed with 0.5 ml H_2O and the reaction mixture was stirred at room temperature for 15 hours. It was then extracted with toluene and the toluene phase was back-extracted with H_2O . The combined aqueous layers were brought to pH 7.5-8.0 (NaHCO_3 , 5%) and the water was evaporated. The residue was purified by flash chromatography (silica gel, 100% MeOH). The fractions containing the compound were evaporated and the residue was dissolved in a minimum quantity of MeOH. Et_2O was then added and the solvents were decanted to give a white gum that was dried under high vacuum. The compound was obtained as a white solid (42 mg, 33%).

35 ^1H NMR ($\text{DMSO}-d_6$): δ 8.25 (s, 1H, purine), 8.14 (s, 1H, purine), 6.5 (bd, 1H, NH), 4.37 (t, 2H, CH_2 linker), 4.03 (m, 2H, CH_2 linker), 3.81 (m, 2H, CH_2 linker), 3.72 (m, 1H, $\text{C}^{\alpha}\text{H}$), 3.60 (m, 2H, CH_2 linker), 3.55-3.89 (m,

6H, $N(CH_3)_2$, 3.05 (m, 2H, $C^{\alpha}H_2$), 1.78-1.39 (m, 4H, $C^{\beta}H_2$, $C^{\gamma}H_2$).

Example 16 (2S,4S)-2-(N,N-dimethylaminopurin-9-yl)-4-(methyloxycarbonyl-D-arginine)-1,3-dioxolane -
Compound #16



10

Step 1: (4S)-2,2-dimethyl-1,3-dioxolane-4-t-butyldiphenylsilylmethanol

To a solution of (4s)-2,2-dimethyl-1,3-dioxolane-4-methanol (1g, 7.57 mmols) in anh. CH_2Cl_2 (76ml), at room temperature, under argon, were added successively imidazole (1.03g., 2eq) and t-BuPh₂SiCl (1.95 ml, 1.1 eq). A white precipitate formed immediately. This suspension was stirred at room temperature for 1 hour and then poured in sat. aq. NaHCO_3 . The phases were separated and the aqueous layer was extracted with CH_2Cl_2 (2x). The combined organic extracts were dried over MgSO_4 , the solids were filtered and the solvents evaporated to give 2.80 g (100%) of the silane as a clear oil.

Step 2: (2S)-3-t-Butyldiphenylsilylpropanetriol

To a solution of the silane (1.01 g, 2.73 mmols) in a 4:1 mixture of THF/ H_2O (15 ml), at room temperature, was added TFAA (0.5 ml, 2.4 eq) and the solution was heated at 50°C for 5 hours. It was then poured in sat. aq. NaHCO_3 / CH_2Cl_2 and the phases were separated. The aqueous layer was extracted with CH_2Cl_2 (2x) and the combined organic extracts were dried over MgSO_4 . The solvents were evaporated and the residue was purified by flash chromatography (silica gel, 1:1 Hex/EtOAc) to give 0.62 g. (70%) of the diol as a clear oil.

Step 3: (2S,4S)-2-benzoyloxymethyl-4-t-Butyldiphenylsilyloxymethyl-1,3-dioxolane

To a solution of the diol (0.62 g, 1.89 mmol) and of the aldehyde (0.31 g, 1eq) in anh. toluene (19 ml), at room temperature, under argon, was added a cat. amount of PPTS. The solution was refluxed for 18 hours, after which it was poured in sat. aq. NaHCO_3 / CH_2Cl_2 . The phases were separated and the aqueous layer was extracted with CH_2Cl_2 (2x). The combined organic extracts were dried over MgSO_4 and

the solvents were evaporated. The residue was purified by flash chromatography (silica gel, 9:1 Hex/EtOAc) to give 0.49 g (55%) of a 5:1 (cis/trans) mixture of the dioxolanes.

5

Step 4: (2S,4S)-2-Hydroxymethyl-4-t-butylidiphenylsilyloxymethyl-1,3-dioxolane

10

To a solution of the benzoate (0.49 g, 1.03 mmol) in anh. MeOH (10.3 ml), at room temperature, under argon, was added MeONa/MeOH 4.37 M (24 μ l, 0.1 eq). The solution was stirred for 18 hours after which it was poured in sat. aq. $\text{NH}_4\text{Cl}/\text{CH}_2\text{Cl}_2$. The phases were separated and the aqueous phase was extracted with CH_2Cl_2 (2x). The combined organic extracts were dried over MgSO_4 , the solids were filtered and the solvents were evaporated. The residue was purified by flash chromatography (silica gel, 3:1 Hex/EtOAc) to give the cis-alcohol (0.26 g, 67%) as a clear oil.

15

20

Step 5: (2S,4S)-2-(N,N-dimethylaminopurin-9-yl)-4-t-butylidiphenylsilyloxymethyl-1,3-dioxolane

25

The compound was prepared using a similar method as in Example 15, step 1.

Step 6: (2S,4R)-2-(N,N-dimethylaminopurin-9-yl)-4-hydroxymethyl-1,3-dioxolane

30

The compound was prepared using a similar method as in Example 15, step 2.

Purification: 10% MeOH/EtOAc

35

$^1\text{H NMR}$ (CDCl_3): δ 8.32 (s, 1H, purine), 7.75 (s, 1H, purine), 5.33 (dd, 1H, $J=2.0, 6.6$, H-2-dioxolane), 5.33 (bs, 1H, OH), 4.45 (dd, 1H, $J=6.6, 14.3$, CH_2 -

purine), 4.20 (dd, 1H, $J=2.0, 14.3$, $\text{CH}_2\text{-purine}$), 4.20 (m, 1H, H-4-dioxolane), 4.05 (d, 2H, $J=7.2$, H-5), 3.78 (d, 1H, $J=13.0$, $\text{CH}_2\text{-OH}$) 3.53 (bs, 6H, $(\text{CH}_3)_2\text{N}$), 3.40 (d, 1H, $J=13.0$, $\text{CH}_2\text{-OH}$).

5

Step 7: (2S,4S)-2-(N,N-dimethylaminopurin-9-yl)-4-(methyloxycarbonyl-D-arginine)-1,3-dioxolane -
Compound #16

10

The compound #16 was prepared using a similar method as in Example 15, step 3.

Purification: MeOH 100%

15

$^1\text{H NMR}$ (DMSO-d_6): δ 8.43 (s, 1H, purine), 8.11 (s, 1H, purine), 6.6 (m, 1H, NH), 5.28, (m, 1H, H-2-dioxolane), 4.39 (m, 2H, $\text{CH}_2\text{-purine}$), 4.26 (m, 1H, H-4-dioxolane), 3.97-3.81 (m, 3H, C^αH , $\text{CH}_2\text{-OCO-D-arginine}$), 3.71 (m, 2H, H-5-dioxolane), 3.39 (bs, 6H, $(\text{CH}_3)_2\text{N}$), 3.07 (m, 2H, C^βH_2), 1.70-1.45 (m, 4H, $\text{C}^\gamma\text{H}_2$, $\text{C}^\delta\text{H}_2$).


20

Example 17

Synthesis of N-(6-Dimethylamino-8-bromopurinyl-9-yl)-Pentoxycarbonyl L-Arginine

25

- Compound #17



$^1\text{H NMR}$ (DMSO-d_6 , 400 MHz, δ in ppm): 9.5 (1H, s, b, COOH), 8.19 (1H, s, purine), 8.1-7.2 (4H, b, guanidine), 6.30 (1H, d, NH), 4.11 (2H, t, N-CH_2), 3.87 (2H, t, $\text{CH}_2\text{-O}$), 3.64 (1H, m, C^αH), 3.39

30

(6H, s, b, N-(CH₃)₂), 3.02 (2H, m, C^δH), 1.8-1.2 (10H, m, C^βH, C^γH, -(CH₂)₃-).


m.p. (softens 115-118°) = 124-127°C.

R_f silica (70% methanol-ethyl acetate) = 0.25

5

Example 18

Synthesis of N-(6-dimethylamino-8-bromopurin-9-yl)-7-pentoxycarbonyl-D-arginine - **Compound #18**




10

¹H NMR (DMSO - d₆, 400 MHz, δ in ppm); 9.08 (1H, br s, COOH); 8.18 (1H, s, purine); 7.9-7.3 (4H, br s, guanidine); 6.34 (1H, d, NH); 4.10 (2H, t, N-CH₂); 3.86 (2H, m, O-CH₂); 3.55 (1H, m, C^αH);

15 3.35 (br s, N-(CH₃)₂); 3.03 (2H, m, C^δH₂); 1.9-1.2 (10H, m, (CH₂)₃, C^γH₂, C^βH₂).

m.p. (softens 116°C) = 122-125°C.

R_f silica (70% methanol-ethyl acetate) = 0.25


Example 19**N-9-purinyl-5-pentanol - Compound #19**

^1H NMR δ (CDCl_3 in ppm): 9.12 (s, 1H, purine), 8.96 (s, 1H, purine), 8.10 (s, 1H, purine), 4.30 (t, 2H, $\text{CH}_2\text{-O}$), 3.63 (t, 2H, $\text{CH}_2\text{-N}$), 1.97 (m, 3H, CH_2 and OH), 1.62 (m, 2H, CH_2), 1.47 (m, 2H, CH_2)

^{13}C NMR (δ CDCl_3 in ppm): 153.09, 151.96, 149.15, 145.80, 134.60, 62.78, 44.38, 32.47, 30.27, 23.57.

Purification 5% MeOH/AcOEt

R_f (silica) 0.29 (5% MeOH/AcOEt).

Example 20**N-9-purinyl-7-pentyloxycarbonyl-D-arginine - Compound #20**


^1H NMR δ (DMSO in ppm): 9.10 (s, 1H, purine), 8.93 (s, 1H, purine), 8.64 (s, 1H, purine), 7.77 (bs, 4H, guanidine), 6.25 (bs, 1H, NH), 4.28 (t, 2H, $\text{CH}_2\text{-O}$), 3.87 (t, 2H, $\text{CH}_2\text{-N}$), 3.58 (m, 1H, C^αH), 3.09 (m, 2H, $\text{CH}_2\text{-N}$), 1.20-1.90 (m, 10H, $5 \times \text{CH}_2$).

Purification: methanol

R_f (silica) = 0.23 (methanol)

Example 21

N-9-purinyl-7-pentyloxycarbonyl-L-arginine -
Compound #21



5

^1H NMR δ (DMSO in ppm): 9.13 (s, 1H, purine), 8.94 (s, 1H, purine), 8.66 (s, 1H, purine), 8.25 (bs, 1H, NH), 7.44 (bs, 3H, guanidine), 6.82 (bs, 1H, NH), 4.28 (t, 2H, $\text{CH}_2\text{-O}$), 3.88 (t, 2H,

$\text{CH}_2\text{-N}$), 3.72 (m, 1H, C^αH), 3.07 (m, 2H, $\text{CH}_2\text{-N}$), 1.19-1.95 (m,

10 10H, $5\times\text{CH}_2$).


^{13}C NMR (δ CD_3OD in ppm): 179.47, 159.21, 158.95, 153.79, 153.41, 140.07, 135.42, 66.06, 57.37, 45.38, 42.66, 31.88, 30.93, 30.11, 26.67, 24.65.

Purification: methanol

15 R_f (silica) = 0.23 (methanol)**Example 22**

Synthesis of N,N-Dimethylaminopurinyl
Pentoxycarbonyl L-Valyl L-Prolyl L-Leucine -
Compound #22


20



- ^1H NMR (CD_3OD , 400 MHz, δ in ppm) 8.22 (1H, s, purine); 8.05 (1H, s, purine); 4.60 (1H, t, C^αH); 4.3-3.6 (8H, n, N-CH_2 , $\text{C}^\delta\text{H}_2$, $\text{CH}_2\text{-O}$, 2 x C^αH); 3.51 (6H, s, b, $\text{N-(CH}_3)_2$); 2.2-1.2 (14H, m, $-(\text{CH}_2)_3-$, 2 x C^βH_2 , C^βH , $\text{C}^\gamma\text{H}_2$, C^γH); 1.0-0.8 (12H, m, 2 x $\text{C}^\beta\text{-CH}_3$, 2 x $\text{C}^\gamma\text{-CH}_3$).
- m.p. = 168°C
- R_f silica (40% methanol-ethyl acetate) = 0.40

Example 23


Synthesis of N,N-Dimethylaminopurinyll
Pentoxycarbonyl L-Isoleucyl L-Prolyl L-
Isoleucine- **Compound #23**



- ^1H NMR (CD_3OD , 400 MHz, δ in ppm); 8.21 (1H, s, purine); 8.03 (1H, s, purine); 4.62 (1 H, t, C^αH); 4.22 (4H, m); 4.03 (2H, m); 3.89 (1H, m, C^αH); 3.67 (1H, d, C^αH); 3.50 (6H, s, b, $\text{N-(CH}_3)_2$); 2.1-1.0 (16H, m, $-(\text{CH}_2)_3-$, C^βH_2 , 2 x C^βH , 3 x $\text{C}^\gamma\text{H}_2$); 0.95 (6H, d, 2 x $\text{C}^\beta\text{CH}_3$); 0.87 (6 H, t, 2 x $\text{C}^\gamma\text{-CH}_3$).
- m.p. (softens 83-86°C) = 93°C
- R_f silica (40% methanol-ethyl acetate) = 0.35

Example 24

Synthesis of N-(6-Cyclopropylaminopurin-9-yl)-
5-pentanol - **Compound #24**



5

¹H NMR (δ CDCl₃ in ppm): 8.46 (s, 1H, purine), 7.77 (s, 1H, purine), 6.42 (bs, 1H, NH), 4.22 (t, 2H, CH₂), 3.09 (bs, 1H, OH), 1.94 (m, 2H, CH₂), 1.63 (m, 2H, CH₂), 1.45 (m, 2H, CH₂), 0.94 (m, 2H, CH₂), 0.69 (m, 2H, CH₂).

10 Colorless oily material


R_f = 0.3 10% methanol/ethyl acetate

Mass spectrum: H⁺ = 262 (HRMS)

Example 25

Synthesis of N-(6-cyclopropylaminopurin-9-yl)-
7-pentyloxycarbonyl-D-arginine - **Compound #25**

15



¹H NMR (δ DMSO in ppm): 8.22 (s, 1H, purine), 8.14 (s, 1H, purine), (bs, 4H, guanidine), 6.28 (d, 1H, NH), 4.13 (t, 2H, CH₂), 3.87 (m, 2H, CH₂), 3.62 (m, 1H, C^αH), 3.02 (m, 2H, CH₂),

1.2-1.8 (m, 11H, 5xCH₂ and CH), 0.69 (m, 2H, CH₂), 0.67 (m, 2H, CH₂).

¹³C NMR (δ, DMSO in ppm): 175.53, 158.20, 157.63, 155.79, 152.62, 150.91, 141.03, 119.92, 63.69, 55.38, 43.12, 41.14,

5 30.10, 29.44, 28.49, 25.49, 24.38, 22.91, 6.78.


m.p. softens 147°C melts 151°C.

R_f = 0.34 (MeOH)

Mass spectrum: H⁺ = 462 (HRMS)

10 **Example 26**

Synthesis of N-(6-cyclopropylaminopurin-9-yl)-7-pentyloxycarbonyl-L-arginine - Compound #26



15 ¹H NMR (δ DMSO in ppm): 8.23 (s, 1H, purine), 8.14 (s, 1H, purine), 7.51 (bs, 4H, guanidine), 6.31 (d, 1H, NH), 4.16 (t, 2H, CH₂), 3.87 (t, 2H, CH₂), 3.62 (m, 1H, C^αH), 3.02 (m, 2H, CH₂), 1.2-1.85 (m, 11H, 5xCH₂ and CH), 0.72 (m, 2H, CH₂), 0.68 (m, 2H, CH₂).

20 ¹³C NMR (δ, CD₃OD in ppm): 179.41, 159.19, 158.95, 157.66, 154.09, 151.00, 143.00, 121.10, 66.12, 57.34, 45.33, 42.67, 31.90, 31.25, 30.14, 26.63, 25.11, 24.61, 8.14.


m.p. 144-146°C

R_f = 0.35 (MeOH)

25 Mass spectrum: M⁺ = 462 (HRMS).

Example 27

Synthesis of N-(6-Azetidinepurin-9-yl)-5-pentanol - Compound #27



¹H NMR (δ, CDCl₃ in ppm): 8.25 (s, 1H, purine), 7.66 (s, 1H, purine), 4.44 (m, 4H, CH₂), 4.10 (t, 2H, CH₂), 3.55 (t, 2H, CH₂), 3.21 (bs, 1H, OH), 2.48 (m, 2H, CH₂), 1.84 (m, 2H, CH₂), 1.54 (m, 2H, CH₂), 1.38 (m, 2H, CH₂).

¹³C NMR (δ, CDCl₃ in ppm): 155.11, 153.42, 150.39, 140.37;

120.38, 62.79, 44.05, 32.57, 30.45, 30.22, 23.45, 18.23, 18.12.


m.p.: 104-106°C

R_f = 0.33 (10% MeOH/AcOEt)

Mass spectrum: M⁺ = 262 (HRMS).

15 **Example 28**

Synthesis of N-(6-Azetidinepurin-9-yl)-7-pentyloxycarbonyl-D-arginine - Compound #28



^1H NMR (δ , CD_3OD in ppm): 7.96 (s, 1H, purine), 7.89 (s, 1H, purine), 4.27 (m, 4H, $2\times\text{CH}_2$), 4.02 (t, 2H, CH_2), 3.79 (m, 3H, CH_2 and C^αH), 2.99 (m, 2H, CH_2), 2.32 (m, 2H, CH_2), 1.17-1.71 (m, 10H, $5\times\text{CH}_2$).

5 ^{13}C NMR (δ , CD_3OD in ppm): 181.56, 159.38, 159.14, 156.16, 153.89, 151.22, 143.21, 120.92, 66.30, 57.15, 48.71 45.24, 42.66, 31.51, 31.26, 30.15, 26.96, 24.64, 18.87.


m.p.: 190-192°C

R_f : 0.25 (methanol)

10 Mass spectrum: $M^+ = 462$ (HRMS)

Example 29

Synthesis of N-(6-Azetidinepurin-9-yl)-7-pentyloxycarbonyl-L-arginine - Compound #29



15

^1H NMR (δ , CD_3OD in ppm): 7.93 (s, 1H, purine), 7.88 (s, 1H, purine), 4.27 (m, 4H, $2\times\text{CH}_2$), 4.01 (t, 2H, CH_2), 3.79 (m, 3H, CH_2 and C^αH), 2.97 (m, 2H, CH_2), 2.32 (m, 2H, CH_2), 1.15-1.74 (m, 10H, $5\times\text{CH}_2$).

20 ^{13}C NMR (δ , CD_3OD in ppm): 179.44, 159.18, 158.95, 156.16, 153.89, 151.21, 143.20, 120.93, 66.12, 57.33, 48.69, 45.26, 42.65, 31.88, 31.33, 31.23, 30.16, 26.63, 24.61, 18.50.


m.p.: (softens at 175°C) melts at 187°C

$R_f = 0.27$ (methanol)

25 Mass spectrum: $M^+ = 462$ (HRMS)

Example 30

Synthesis of trans-(N-6-chloropurin-9-yl)-4-methyl-cyclohexyl-methanol - **Compound #30**



5

^1H NMR (CDCl_3 , 400MHz, δ in ppm); 8.73 (1H, s, purine); 8.05 (1H, s, purine); 4.12 (2H, d, N- CH_2); 3.43 (2H, d, O- CH_2); 1.89 (1H, m, CH); 1.84-1.64 (4H, m, CH_2 -cyclohexane); 1.56 (1H, br s, OH); 1.45 (1H, m, CH); 1.14-0.85 (4H, m, CH_2 -cyclohexane).


10 m.p. (softens 176°C) = 178°C

R_f = 0.4 (ethyl acetate)

Example 31

Synthesis of trans-(N-6-dimethylaminopurin-9-yl)-4-methyl-cyclohexyl-methanol - **Compound #31**

15



^1H NMR (CDCl_3 , 300MHz, δ in ppm); ; 8.29 (1H, s, purine); 7.63 (1H, s, purine); 3.97 (2H, d, N- CH_2); 3.49 (6H, br s, N- $(\text{CH}_3)_2$); 3.38 (2H, d, O- CH_2); 2.46 (1H, br s, OH); 1.84 (1H, br m, CH -cyclohexane); 1.71 (4H, m, 2 x CH_2 -cyclohexane); 1.40 (1H, m, CH -cyclohexane); 0.90 (4H, m, CH_2 -cyclohexane).

^{13}C NMR (CDCl_3 , 400MHz, δ in ppm); 154.9, 152.3, 150.6, 138.7, 120.1, 68.2, 49.7, 40.2, 38.5, 38.2, 29.9, 28.6.


25 m.p. = 151-153°C

$R_f = 0.44$ (10% methanol-ethyl acetate)

Example 32

Synthesis of trans-(N-6-dimethylaminopurin-9-yl)-4-methyl-cyclohexyl-methyloxycarbonyl-D-arginine - **Compound #32**

5



^1H NMR (DMSO- d_6 , 400MHz, δ in ppm); 9.4 (1H, br s, COOH); 8.19 (1H, s, purine); 8.11 (1H, s, purine); 8.0-7.2 (4H, br, guanidine); 6.28 (1H, d, NH); 3.98 (2H, d, N-CH $_2$); 3.69 (2H, d, O-CH $_2$); 3.61 (1H, m, C $^\alpha$ H); 3.43 (6H, br s, N-CH $_3$) $_2$; 3.00 (2H, br, C $^\delta$ H $_2$); 1.9-0.8 (14H, m, C $^\beta$ H $_2$, C $^\gamma$ H $_2$, 2 x CH-cyclohexane, 4 x CH $_2$ -cyclohexane).

^{13}C NMR (DMSO- d_6 , 400MHz, δ in ppm); 174.8, 156.8, 155.0, 153.8, 151.2, 150.0, 139.6, 118.7, 78.7, 67.9, 54.6, 48.2, 48.1, 37.1, 36.5, 29.3, 28.8, 27.8, 24.6.


m.p. (softens 157°C) = 164-166°C

$R_f = 0.35$ (methanol)

20

Example 33

Synthesis of trans-(N-6-hydroxypurin-9-yl)-4-methyl-cyclohexyl-methanol -Compound #33



5 ^1H NMR (CD_3OD , 400MHz, δ in ppm); 8.05 (2H, s, purine); 4.10 (2H, d, N- CH_2); 3.35 (2H, d, O- CH_2); 2.0-0.9 (10 H, m, 2 x CH_2 -cyclohexane, 4 x CH_2 -cyclohexane)

^{13}C NMR (CD_3OD , 400MHz, δ in ppm); 156.7, 148.1, 144.1, 140.2, 122.7, 66.1, 48.7, 39.2, 37.5, 28.7, 27.6.


10 m.p. > 200°C

R_f = 0.35 (20% methanol-ethyl acetate)

Example 34

Synthesis of trans-(N-6-methoxypurin-9-yl)-4-methyl-cyclohexyl-methanol - Compound #34

15



^1H NMR (CDCl_3 , 300MHz, δ in ppm); 8.52 (1H, s, purine); 7.84 (1H, s, purine); 4.17 (3H, s, O- CH_3); 4.12 (2H, d, N- CH_2); 3.43 (2H, d, O- CH_2); 1.89 (1H, m, CH); 1.84-1.64 (4H, m, CH_2 -cyclohexane); 1.56 (1H, br s, OH); 1.45 (1H, m, CH); 1.14-0.85 (4H, m, CH_2 -cyclohexane).


m.p. (softens 159°C) = 162°C

R_f = 0.25 (ethyl acetate)

25

Example 35


Synthesis of cis-(N-6-dimethylaminopurin-9-yl)-4-methyl-cyclohexyl-methanol - Compound# 35



¹H NMR (CDCl₃, 300MHz, δ in ppm); ; 8.31 (1H, s, purine); 7.66
 5 (1H, s, purine); 4.08 (2H, d, N-CH₂); 3.55 (2H, d, O-CH₂); 3.50
 (6H , br s, N-(CH₃)₂); 3.28 (1H, br s, OH); 2.12 (1H, m, CH);
 1.67 (1H, m, CH); 1.5-1.3 (8H, m, CH₂-cyclohexane).
¹³C NMR (CDCl₃, 300MHz, δ in ppm); 155.4, 152.7, 151.1, 139.1,
 120.5, 65.9, 47.7, 39.1, 38.3, 36.3, 26.6, 25.4.
 10 m.p. 153-156°C
 R_f = 0.3 (10% methanol-ethyl acetate)

Example 36

Synthesis of cis-(N-6-dimethylaminopurin-9-yl)-
 4-methyl-cyclohexyl-methyloxycarbonyl-D-
 15 arginine - **Compound #36**



¹H NMR (DMSO-d₆, 400MHz, δ in ppm); 9.28 (1H, br s, COOH); 8.19
 20 (1H, s, purine); 8.13 (1H, s, purine); 8.0-7.2 (4H, br,
 guanidine); 6.34 (1H, d, NH); 4.10 (2H, d, N-CH₂); 3.85 (2H, d,
 O-CH₂); 3.65 (1H, m, C^αH); 3.44 (6H, br s, N-(CH₃)₂); 3.02 (2H,

m, $C\delta H_2$); 2.09 (1H, m, CH); 1.8-1.2 (14H, m, $C\beta H_2$, $C\gamma H_2$, 2 x CH -cyclohexane, 4 x CH_2 -cyclohexane).


^{13}C NMR (DMSO- d_6 , 400MHz, δ in ppm); 175.2, 157.7, 155.2, 154.1, 151.8, 150.2, 139.9, 119.3, 66.4, 55.3, 46.1, 48.0, 34.9, 34.7, 29.9, 25.5, 25.1, 24.4.

m.p. (softens 153°C) = 168-170°C

R_f = 0.35 (methanol)

Example 37

Synthesis of N-(6-dimethylaminopurin-9-yl) 7-pentoxycarbonyl-D-citrulline - **Compound #37**



1H NMR (DMSO - d_6 , 400 MHz, δ in ppm); 8.19 (1H, s, purine); 8.15 (1H, s, purine); 6.21 (1H, d, NH); 6.11 (1H, s, $NCO-NH$); 5.42 (2H, s, NH_2); 4.14 (2H, t, $N-CH_2$); 3.86 (2H, m, $O-CH_2$); 3.56 (1H, m, $C\alpha H$); 3.35 (6H, br s, $N-(CH_3)_2$); 2.87 (2H, m, $C\delta H_2$);

1.9-1.2 (10H, m, $(CH_2)_3$, $C\gamma H_2$, $C\beta H_2$).


^{13}C NMR (CD_3OD , 400 MHz, δ in ppm); 173.6, 158.4, 155.0, 153.8, 151.2, 149.7, 139.3, 118.7, 62.8, 54.8, 42.3, 37.4, 29.8, 28.5, 27.6, 25.7, 22.0.

m.p. (softens 172-176°C) = 178-181°C

R_f = 0.20 (40% methanol-ethyl acetate)

Example 38

Synthesis of N-(6-methylaziridinepurin-9-yl)-5-pentanol - **Compound #38**



^1H NMR (δ , CDCl_3 in ppm): 8.54 (s, 1H, purine), 7.90 (s, 1H, purine), 4.22 (t, 2H, CH_2), 3.61 (t, 2H, CH_2), 2.78 (m, 1H, CH),
 5 2.65 (d, 1H, CH_2), 2.40 (d, 1H, CH_2), 2.39 (bs, 1H, OH), 1.94 (m, 2H, CH_2), 1.59 (m, 2H, CH_2), 1.50 (d, 3H, CH_3), 1.40 (m, 2H, CH_2).

^{13}C NMR (δ , CDCl_3 in ppm): 163.30, 152.99, 151.99, 142.80, 126.11, 62.81, 44.48, 35.97, 34.89, 32.51, 30.38, 23.50, 18.48.


10 Low melting point.

$R_f = 0.4$ (20% MeOH/AcOEt)

Mass spectrum: $M^+ = 262$

Example 39

Synthesis of N-(6-methylaziridine purine-9-yl)-
 15 7-pentyloxycarbonyl-D-arginine - **Compound #39**




^1H NMR (CD_3OD in ppm): 8.29 (s, 1H, purine), 8.14 (s, 1H, purine),
 20 4.10 (t, 2H, CH_2), 3.79 (m, 3H, $1 \times \text{CH}_2$ and C^αH), 2.97 (m, 2H, CH_2), 2.62 (m, 1H, CH), 2.45 (d, 1H, CH_2), 2.19 (d, 1H, CH_2), 1.2-1.76 (m, 13H, $5 \times \text{CH}_2$ and $1 \times \text{CH}_3$).

m.p.: (softens at 190°C) melts at 200°C

R_f: 0.4 (methanol)


Mass spectrum: M⁺ = 462



- 5 **Example 40** N,N-(6-Dimethylaminopuriny-9-yl)-7-thioethoxy-ethoxycarbonyl-D-arginine - Compound #40



Example 41

meta-(N-6-Dimethylaminopurinyl-9-yl) methyl-
benzyloxycarbonyl-D-arginine - **Compound #41**

**Compound #41**

Example 425-(N-6-Dimethylaminopurinyl-9-yl)-3-pentynyl-1-oxycarbonyl-D-arginine - **Compound #40****Example 43**Synthesis of N-[6-(1-methyl-2-acetoxy)-ethylaminopurin-9-yl]-5-pentanol - **Compound #43**

^1H NMR (δ , CDCl_3 in ppm): 8.36 (s, 1H, purine), 7.76 (s, 1H, purine), 6.58 (bs, 1H, NH), 5.18 (m, 1H, OH), 4.22 (t, 2H, CH_2), 3.92 (bs, 1H, CH), 3.63 (t, 2H, CH_2), 2.05 (s, 3H, CH_3), 1.3-1.9 (m, $4\times\text{CH}_2$, $1\times\text{CH}_3$).

5 173.04, 156.6, 155.8, 154.2, 142.8, 120.5, 71.66, 68.61, 63.10, 45.43, 33.54, 31.42, 24.54, 21.69, 18.25.

Low melting point


R_f = 0.5 15% MeOH/AcOEt

Mass spectrum: M^+ = 322

10

Example 44

Synthesis of N-[6-(1-methyl-2-acetoxy), ethylaminopurin-9-yl]-7-pentyloxy-carbonyl-D-arginine - **Compound #44**



15

^1H NMR (δ , CD_3OD in ppm): mixture of isomers, 8.05 (s, 1H, purine), 7.89 (s, 1H, purine), 4.92 (m, 1H, CH), 4.03 (t, 2H, CH_2), 3.78 (m, 3H, CH_2 and $\text{c}^{\alpha}\text{H}$), 3.46 (d, 2H, CH_2), 2.99 (m, 2H, CH_2), 1.8 (s, 3H, CH_3), 1.1-1.79 (m, 13H, $5\times\text{CH}_2$ and $1\times\text{CH}_3$).

20

^{13}C NMR (δ , CD_3OD in ppm): mixture of isomers, 179.50, 159.19, 158.97, 156.88, 154.21, 154.14, 142.85, 142.75, 120.95, 68.13, 66.91, 66.11, 57.36, 45.32, 42.65, 31.89, 31.73, 31.25, 30.15, 30.04, 26.67, 24.61, 21.56, 18.09.


25 m.p.: (softens at 177°C) melts at 185°C

R_f : 0.35 (methanol)

Mass spectrum: M^+ = 522.

Example 45

Synthesis of N-(2,6-Dichloropurin-9-yl)-5-pentanol - **Compound #45**



5

^1H NMR (δ , CDCl_3 in ppm): 8.11 (s, 1H, purine), 4.29 (t, 2H, CH_2), 3.66 (t, 2H, CH_2), 2.00 (m, 2H, CH_2), 1.64 (m, 2H, CH_2), 1.48 (m, 2H, CH_2), 1.3 (t, 1H, OH).

^{13}C NMR (δ , CDCl_3 in ppm): 163.3, 150.2, 149.3, 148.01, 128.00,

10 63.20, 44.80, 29.70, 26.00, 22.4.


m.p.: 133-135°C

R_f : 0.4 5% methanol/ethyl acetate

Mass spectrum: $M^+ = 260$ (HRMS).

15 **Example 46**

Synthesis of N-(2,6-Dichloropurin-9-yl)-7-pentyloxycarbonyl-D-arginine - **Compound #46**



20 ^1H NMR (δ , DMSO in ppm): 9.33 (s, 1H, COOH), 8.75 (s, 1H, purine), 7.3-7.8 (bs, 4H, guanidine), 6.28 (d, 1H, NH), 4.23 (t, 2H, CH_2), 3.86 (t, 2H, CH_2), 3.61 (m, 1H, C^αH), 3.015 (m, 2H, CH_2), 1.2-1.9 (m, 10H, $5 \times \text{CH}_2$).

m.p.: Softens at 136°C melts at 147°C


R_f: 0.46 methanol

Mass spectrum: M⁺ = 476

Example 47

Synthesis of N-(2,6-Dichloropurin-9-yl)-7-pentyloxycarbonyl-L-arginine - **Compound #47**

5



¹H NMR (δ, CD₃OD in ppm): 8.38 (s, 1H, purine), 4.12 (t, 2H, CH₂), 3.80 (m, 3H, CH₂ and C^αH), 2.97 (m, 2H, CH₂), 1.2-1.8 (m, 10H, 5xCH₂).

m.p.: Softens at 137°C, melts at 147°C


R_f: 0.45 (methanol)

Mass spectrum: M⁺ = 476

15

Example 48

N-(2-Amino, 6-N, N-Dimethylaminopurin-9-yl)-5-pentanol - **Compound #48**



20

^1H NMR (δ in CDCl_3 ppm): 7.46 (s, 1H, purine), 4.70 (bs, 2H, NH_2), 4.04 (t, 2H, CH_2), 3.65 (t, 2H, CH_2), 3.46 (bs, 6H, 2 x CH_3), 1.95 (m, 2H, CH_2), 1.65 (m, 2H, CH_2), 1.42 (m, 2H, CH_2)

^{13}C NMR (δ in CD_3OD ppm):

5 158.27, 154.08, 150.74, 136.12, 112.96, 60.28, 41.97, 36.50, 30.71, 28.38, 21.64.

m.p.: 139-141°C


R_f : 0.55 (15% Methanol/Ethyl acetate)

Mass spectrum: M^+ = 265.

10

Example 49

Synthesis of N-(6-dimethylamino-8-methylthiopurin-9-yl) 5-pentanol - Compound #49




15

^1H NMR (CDCl_3 , 400MHz, δ in ppm): 8.24 (1H, s, purine); 4.08 (2H, t, N- CH_2); 3.61 (2H, t, O- CH_2); 3.49 (6H, br s, N-(CH_3)₂); 2.70 (3H, s, S- CH_3); 1.81 (2H, p, CH_2); 1.67 (1H, br s, OH); 1.59 (2H, p, CH_2); 1.39 (2H, p, CH_2).

20 ^{13}C NMR (CDCl_3 , 400MHz, δ in ppm): 152.30, 151.69, 150.29, 146.47, 119.39, 61.58, 41.77, 37.45, 31.28, 28.08, 21.81, 13.43.

Example 50

Synthesis of N-(6-dimethylamino-8-methylthiopurin-9-yl) 7-pentoxycarbonyl-D-arginine - **Compound #50**




5

^1H NMR (DMSO- d_6 , 400MHz, δ in ppm); 8.13 (1H, s, purine); 8.0-7.2 (4H, br, guanidine); 6.32 (1H, d, NH); 4.01 (2H, t, N-CH $_2$); 3.86 (2H, t, O-CH $_2$); 3.65 (1H, m, C $^{\alpha}$ H); 3.41 (6H, br s, N-(CH $_3$) $_2$); 3.02 (2H, br, C $^{\delta}$ H $_2$); 1.8-1.2 (10H, m, C $^{\beta}$ H $_2$, C $^{\gamma}$ H $_2$, - (CH $_2$)-).

15

Example 51

Synthesis of N-(6-methoxypurin-9-yl) 5-pentanol - **Compound #51**



20

^1H NMR (CDCl_3 , 400MHz, δ in ppm); 8.43 (1H, s, purine); 7.86 (1H, s, purine); 4.18 (2H, t, N- CH_2); 4.09 (3H, s, O- CH_3); 3.55 (2H, t, O- CH_2); 3.09 (1H, br s, OH); 1.86 (2H, m, CH_2); 1.53 (2H, m, CH_2); 1.37 (2H, m, CH_2).


5 ^{13}C NMR (CDCl_3 , 400MHz, δ in ppm); 160.0, 150.9, 141.2, 120.4, 60.9, 53.2, 43.1, 30.9, 28.8, 22.0.

m.p. = 150°C

R_f = 0.30 (15% methanol-ethyl acetate)

10 Example 52

Synthesis of N-(6-methoxypurin-9-yl) 7-pentoxycarbonyl-D-arginine - **Compound #52**



^1H NMR ($\text{DMSO}-d_6$, 300MHz, δ in ppm); 8.51 (1H, s, purine); 8.39 (1H, s, purine); 8.0-7.3 (4H, br, guanidine); 6.29 (1H, d, NH); 4.22 (2H, t, N- CH_2); 4.08 (3H, s, O- CH_3); 3.86 (2H, t, O- CH_2); 3.62 (1H, m, C^αH); 3.02 (2H, br, $\text{C}^\delta\text{H}_2$); 1.8-1.2 (10H, m, C^βH_2 , $\text{C}^\gamma\text{H}_2$, $(\text{CH}_2)_3$).


15 ^{13}C NMR (CDCl_3 , 400MHz, δ in ppm); 205.9, 175.8, 160.6, 157.7, 155.8, 152.4, 151.8, 120.9, 63.7, 55.4, 54.2, 43.6, 39.1, 30.1, 29.3, 28.5, 25.5, 22.9.

m.p. (softens 132°C) = 148°C

R_f = 0.35 (40% methanol-ethyl acetate)

Example 53

Synthesis of N-(2-chloro-6-methoxypurin-9-yl)-
7-pentylloxycarbonyl-D-arginine - **Compound #53**



5 ^1H NMR (δ , DMSO in ppm)

9.41 (bs, 1H, COOH), 8.42 (s, 1H, purine), 7.3-7.8 (bd, 4H, guanidine), 6.28 (d, 1H, NH), 4.08 (s, 3H, CH₃), 3.87 (t, 2H, CH₂), 4.18 (t, 2H, CH₂), 4.08 (s, 3H, CH₃), 3.87 (t, 2H, CH₂),

4.08 (s, 3H, CH₃), 3.87 (t, 2H, CH₂), 3.61 (m, 1H, C ^{α} H), 3.04

10 (m, 2H, CH₂), 1.22-1.87 (m, 10H, 5 X CH₂).


m.p.: Softens at 128°C, melts at 141°C

R_f: 0.45 (Methanol)

Mass spectrum: M⁺ = 471.

15 **Example 54**

Synthesis of N-(6-dimethylaminopurin-9-yl) 7-
pentoxycarbonyl-D-ornithine - **Compound #54**



^1H NMR (DMSO- d_6 , 400MHz, δ in ppm); 8.20 (1H, s, purine); 8.12 (1H, s, purine); 6.21 (1H, d, NH); 4.10 (2H, t, N-CH $_2$); 3.87 (2H, t, O-CH $_2$); 3.59 (1H, m, C $^{\alpha}$ H); 3.4 (br, N-(CH $_3$) $_2$, NH $_2$), 2.70 (2H, m, C $^{\delta}$ H $_2$); 1.9-1.2 (10H, m, (CH $_2$) $_3$, C $^{\beta}$ H $_2$, C $^{\gamma}$ H $_2$).

5 ^{13}C NMR (CD $_3$ OD, 400MHz, δ in ppm); 176.3, 156.2, 153.8, 150.7, 148.8, 138.9, 118.5, 63.5, 54.2, 42.5, 38.0, 37.0, 28.6, 28.3, 27.2, 22.4, 21.7.


m.p. (softens 185°C) = 189-190°C

R $_f$ = 0.20 (methanol)

10

Example 55

Synthesis of N-(6-dimethylaminopurin-9-yl) 7-pentoxycarbonyl-L-ornithine - **Compound #55**




15

Spectral properties were identical with compound #54.

Example 56

Synthesis of N-(6-dimethylaminopurin-9-yl) 7-pentoxycarbonyl-L-valine - **Compound 56**

20



^1H NMR (DMSO - d_6 , 400 MHz, δ in ppm); 8.19 (1H, s, purine); 8.16 (1H, s, purine); 6.30 (1H, d, NH); 4.13 (2H, t, N-CH $_2$);

3.87 (2H, m, O-CH₂); 3.64 (1H, m, C^αH); 3.4 (br s, N-(CH₃)₂);

1.80 (2H, p, CH₂,); 1.25 (2H, p, CH₂,); 0.79 (3H, d, C^γH₃); 0.75

(3H, d, C^γH₃).


¹³C NMR (CD₃OD, 400 MHz, δ in ppm); 174.6, 156.7, 153.7, 150.5,

148.9, 138.6, 118.6, 63.4, 59.2, 42.3, 36.729.6, 28.3, 27.3, 21.7, 17.5, 15.9.

m.p. (softens 140°C) = 172-176°C


R_f = 0.20 (30% methanol-ethyl acetate)

- 10 **Example 57** Synthesis of N-(6-dimethylaminopurin-9-yl) 7-pentoxycarbonyl-D-valine - **Compound #57**



- 15 Spectral properties were identical with compound #56.

- Example 58** Synthesis of N(N,N-dimethylaminopurin-9-yl)-7-pentylloxycarbonyl ethylamine hydrochloride - **Compound #58**



20

¹H NMR (δ in DMSO ppm): 8.40 (s, 1H, purine), 8.43 (s, 1H, purine), 8.04 (bs, 3H, NH₃), 4.24 (t, 2H, CH₂), 4.02 (t, 2H, CH₂), 2.99 (m, 2H, CH₂), 2.67 (t, 2H, CH₂), 1.83 (m, 2H, CH₂),

25 1.62 (m, 2H, CH₂), 1.28 (m, 2H, CH₂).


R_f: 0.3 10% Methanol/Ethylacetate

Mass spectrum: M⁺ = 321

Example 59

Synthesis N-(6-Mercaptopurin-9-yl)-pentanol -
Compound #59

5




¹HNMR (δ DMSO in ppm): 8.30 (s, 1H, purine), 8.18 (s, 1H, C₂-
10 purine), 4.34 (t, 1H, OH), 4.15 (t, 2H, CH₂-O), 3.34 (t, 2H,
CH₂-N), 1.82 (m, 2H, CH₂), 1.42 (m, 2H, CH₂), 1.24 (m, 2H, CH₂).

R_f: 0.57 30% Methanol/Ethylacetate

Mass spectrum: M⁺ = 239

15 **Example 60**

Synthesis of N-(6-Methylthiopurin-9-yl)-
pentanol - Compound #60



20 ¹HNMR (δ CDCl₃ in ppm): 8.74 (s, 1H, purine), 7.95 (s, 1H,
purine), 4.27 (t, 2H, CH₂-N), 3.65 (t, 2H, CH₂-O), 2.74 (s, 3H,
SCH₃), 1.94 (m, 2H, CH₂), 1.60 (m, 2H, CH₂), 1.43 (m, 2H, CH₂).

¹³CNMR (δ CD₃OD in ppm): 163.23, 153.42, 149.96, 145.89, 132.48,
63.08, 45.60, 33.62, 31.24, 24.54, 12.29.

25 m.p.: 95-97°C


R_f: 0.22 (Ethylacetate)

Mass spectrum: M⁺ = 253

Example 61

Synthesis of N-(6-chloropurin-9-yl) 4-butanol -


Compound #61



¹H NMR (CDCl₃, 400 MHz, δ in ppm): 8.66 (1H, s, purine), 8.16 (1H, s, purine), 4.33 (2H, t, N-CH₂), 3.67 (2H, t, O-CH₂), 3.04 (1H, br s, OH), 2.01 (2H, p, CH₂), 1.55 (2H, p, CH₂).
m.p. = 97°C

Example 62


Synthesis of N-(6-dimethylaminopurin-9-yl) 4-butanol - Compound #62



¹H NMR (CDCl₃, 400 MHz, δ in ppm): 8.24 (1H, s, purine), 7.68 (1H, s, purine), 4.33 (2H, t, N-CH₂), 3.89 (1H, br s OH), 3.64 (2H, t, O-CH₂), 3.46 (6H, br, N-(CH₃)₂), 1.92 (2H, p, CH₂), 1.53 (2H, p, CH₂).
m.p. = 78°C

Example 63

Synthesis of N-(6-dimethylaminopurin-9-yl)-6-butoxycarbonyl-D-arginine - Compound #63




^1H NMR (DMSO- d_6 , 400 MHz, δ in ppm); 8.20 (1H, s, purine), 8.16 (1H, s, purine), 8.1-7.3 (4H, br, guanidine), 6.40 (1H, d, NH),
 5 4.16 (2H, t, N-CH_2), 3.91 (2H, t, O-CH_2), 3.65 (1H, m, C^βH), 3.4 (6H, br, $\text{N-(CH}_3)_2$), 3.02 (2H, m, C^βH), 1.9-1.3 (8H, m, C^βH , C^γH , -
 (CH_2) $_2$ -).

m.p. (softens 85°C) = 140-142°C

10 Example 64

Synthesis of N-(6-dimethylaminopurin-9-yl)-6-butoxycarbonyl-L-arginine - **Compound #64**




Spectral properties were identical with compound #63 .

15 m.p. (softens 85°C) = 139-142°C

Example 65

Synthesis of N-(6-chloropurin-9-yl)-6-hexanol - **Compound #65**



^1H NMR (δ , CDCl_3 in ppm): 8.69 (s, 1H, purine), 8.11 (s, 1H, purine), 4.27 (t, 2H, CH_2), 3.58 (t, 2H, CH_2), 2.21 (bs, 1H, OH), 1.91 (m, 2H, CH_2), 1.43 (m, 2H, CH_2), 1.35 (m, 4H, $2\times\text{CH}_2$).

^{13}C NMR (δ , CDCl_3 in ppm): 152.45, 151.60, 145.69, 132.16, 112.00, 63.00, 44.96, 32.86, 30.39, 26.87, 25.67.


m.p. = 84-86°C

R_f = 0.5 10% (methanol/ethyl acetate)

10 Mass spectrum: M^+ = 255

Example 66

Synthesis of N-(6-N,N-dimethylaminopurin-9-yl)-6-hexanol - **Compound #66**



15

^1H NMR (δ , CDCl_3 in ppm): 8.35 (s, 1H, purine), 7.71 (s, 1H, purine), 4.17 (t, 2H, CH_2), 3.61 (t, 2H, CH_2), 3.53 (bs, 6H, $2\times\text{CH}_3$), 1.89 (m, 2H, CH_2), 1.71 (bs, 1H, OH), 1.55 (m, 2H, CH_2), 1.45 (m, 4H, $2\times\text{CH}_2$).

^{13}C NMR (δ , CDCl_3 in ppm): 154.44, 152.90, 150.95, 138.72, 120.53, 63.04, 44.08, 39.28, 32.95, 30.61, 26.80, 25.64.


m.p. 75-77°C

R_f = 0.48 10% methanol/ethyl acetate

25 Mass spectrum: M^+ = 264

Example 67

Synthesis of N-(6-N,N-dimethylaminopurin-9-yl)-8-hexyloxycarbonyl-D-arginine - **Compound #67**




^1H NMR (δ , CD_3OD in ppm): 7.98 (s, 1H, purine), 7.31 (s, 1H, purine), 3.98 (t, 2H, CH_2), 3.78 (m, 3H, CH_2 and $\text{C}^{\alpha}\text{H}$), 3.27 (bs, 6H, $2\times\text{CH}_3$), 2.96 (t, 2H, CH_2), 1.1-1.78 (m, 12H, $6\times\text{CH}_2$).

Example 68

Synthesis of N-6-N,N-dimethylaminopurine-9-yl)-8-hexyloxycarbonyl-L-arginine - Compound #68


10



^1H NMR (δ , CD_3OD in ppm): 8.00 (s, 1H, purine), 7.82 (s, 1H, purine), 4.00 (t, 2H, CH_2), 3.80 (m, 3H, CH_2 and $\text{C}^{\alpha}\text{H}$), 3.29 (bs, 6H, $2\times\text{CH}_3$), 2.97 (t, 2H, CH_2), 1.13-1.72 (m, 12H, $6\times\text{CH}_2$).

Example 69

Synthesis of cis-(N-6-hydroxypurin-9-yl)-4-methyl-cyclohexyl-methanol - Compound #69




¹H NMR (CD₃OD, 400 MHz, δ in ppm): 8.08 (1H, s, purine), 8.07 (1H, s, purine), 4.21 (2H, d, N-CH₂), 3.49 (2H, d, O-CH₂), 2.16 (1H, m, CH), 1.7-1.2 (9H, m, CH₂-cyclohexane, CH).

m.p. >200°C


R_f = 0.3 (20% methanol-ethyl acetate)

Example 70 Synthesis of cis-(N-6-hydroxypurin-9-yl)-4-methyl-cyclohexyl-methyloxycarbonyl-D-arginine
10 - Compound #70




15 ¹H NMR (CD₃OD, 400 MHz, δ in ppm): 8.10 (1H, s, purine), 8.09 (1H, s, purine), 4.24 (2H, d, N-CH₂), 3.65 (1H, m, C ^{α} H), 3.52 (2H, d, O-CH₂), 2.95 (2H, m, C ^{δ} H₂), 2.2-1.2 (14H, m, 2xCH-cyclohexane, 4xCH₂-cyclohexane, C ^{β} H₂, C ^{γ} H₂).

20 **Example 71** Synthesis of trans-(N-6-hydroxypurin-9-yl)-4-methyl-cyclohexyl-methyloxycarbonyl-D-arginine
- Compound #71




- ^1H NMR (CD_3OD , 300 MHz, δ in ppm): 8.09 (2H, s, purine), 4.12 (2H, d, N-CH_2), 3.68 (1H, m, C^αH), 3.36 (2H, d, O-CH_2), 3.01 (2H, m, C^βH_2), 2.0-0.9 (14H, m, $2\times\text{CH-cyclohexane}$, $4\times\text{CH}_2\text{-cyclohexane}$, C^βH_2 , $\text{C}^\gamma\text{H}_2$).
 m.p. $>200^\circ\text{C}$
 $R_f = 0.2$ (methanol)

- 10 **Example 72** Synthesis of N-(6-N,N dimethylaminopurin-9-yl)-5-pentylamine hydrochloride salt - **Compound #72**



- 15 ^1H NMR (δ , DMSO in ppm): 8.20 (s, 1H, purine), 8.16 (s, 1H, purine), 7.84 (bs, 3H, NH_3), 4.14 (t, 2H, CH_2), 3.44 (bs, 6H, $2\times\text{CH}_3$), 2.73 (t, 2H, CH_2), 1.81 (m, 2H, CH_2), 1.56 (m, 2H, CH_2), 1.25 (m, 2H, CH_2).

- 20 **Example 73** Synthesis of N-(6-methylaziridinepurin-9-yl)-7-pentyloxycarbonyl-L-arginine - **Compound #73**




Spectral data of compound #73 was comparable to that reported for compound #39 .

5

Example 74

(2S,4S)-2-(N,N-Dimethylaminopurin-9-yl)-4-hydroxymethyl-1,3-dioxolane - **Compound #74**




10 ^1H NMR (CDCl_3): δ 8.32 (s, 1H, purine), 7.75 (s, 1H, purine),
 5.33 (dd, 1H, $J = 2.0, 6.6$, H-2-dioxolane), 5.33 (bs, 1H, OH),
 4.45 (dd, 1H, $J = 6.6, 14.3$, CH₂-purine), 4.20 (dd, 1H, $J = 2.0,$
 14.3, CH₂-purine), 4.20 (m, 1H, H-4-dioxolane), 4.05 (d, 2H, $J =$
 7.2, H-5), 3.78 (d, 1H, $J = 13.0$, CH₂-OH), 3.53 (bs, 6H,
 15 (CH₃)₂N), 3.40 (d, 1H, $J = 13.0$, CH₂-OH).

Example 75


(1S,3R) and (1R,3S)-1-(N-6-Dimethylaminopurin-9-yl)methyl-3-cyclopentane methanol -
Compound #75

20




^1H NMR (CDCl_3 , 300 MHz): δ 8.32 (s, 1H, purine), 7.71 (s, 1H, purine), 4.18 (dd, 1H, $J = 8.6, 13.7$), 4.06 (dd, 1H, $J = 6.7, 13.7$), 3.61-3.53 (m, 8H), 3.00 (bs, 1H, OH), 2.48 (m, 1H), 2.17 (m, 1H), 1.88-1.68 (m, 3H), 1.53 (m, 1H), 1.43 (m, 1H), 1.08 (m, 1H).

Example 76 (1S,3R) and (1R,3S)-1-(N-6-Dimethylaminopurin-9-yl)methyl-3-(methoxycarbonyl-D-arginine)cyclopentane - **Compound #76**




Example 77 N,N-(6-Dimethylaminopurin-9-yl)-7-ethylaminoethanol - **Compound #77**



5 ^1H NMR (CDCl_3 , 400 MHz): δ 8.34 (s, 1H, purine), 7.79 (s, 1H, purine), 4.29 (t, 2H, $J=5.8$, $-\text{CH}_2-$), 3.62 (m, 2H, $-\text{CH}_2-$), 3.54 (bs, 6H, $(\text{CH}_3)_2\text{N}$), 3.11 (t, 2H, $J=5.8$, $-\text{CH}_2-$), 2.81 (t, 2H, $J=5.2$, $-\text{CH}_2-$), 2.05 (bs, 2H, NH and OH).

10 **Example 78** N,N-(6-Dimethylaminopurin-9-yl)-7-ethylaminoethoxycarbonyl-D-arginine - **Compound #78**




15 ^1H NMR (CDCl_3 , 300 MHz): δ 9.36 (m, 1H), 8.19 (s, 1H, purine), 8.11 (s, 1H, purine), 6.38 (d, 1H, $J=7.0$, NH carbamate), 4.17 (t, 2H, $J=6.1$, $-\text{CH}_2-$), 3.91-3.87 (m, 2H, $-\text{CH}_2-$), 3.65 (m, 1H, $\text{CH}-\text{COOH}$), 3.43 (bs, 6H, $(\text{CH}_3)_2\text{N}$), 3.03-3.01 (m, 2H, $\text{CH}_2-\text{NHC}(\text{NH})\text{NH}_2$), 2.90 (t, 2H, $J=6.1$, $-\text{CH}_2-$), 2.68 (t, 2H, $J=5.6$, $-\text{CH}_2-$), 1.64-1.44 (m, 4H, $\text{CH}_2-\text{CH}_2-\text{CH}_2\text{NHC}(\text{NH})\text{NH}_2$).

20

Example 79

N,N-(6-Dimethylaminopurin-9-yl)-7-ethylaminoethoxycarbonyl-L-arginine -


Compound #79

5

Spectral properties were identical with compound #78.

Example 80

5-(N-6-Dimethylaminopurin-9-yl)-3-pentyn-1-ol -

Compound #80


10

^1H NMR (CDCl_3): δ 8.34 (s, 1H, H-2 purine), 7.89 (s, 1H, H-8 purine), 4.91 (m, 2H, $\text{CH}_2\text{-N}$), 3.74 (t, 2H, $J = 6.2$, $\text{CH}_2\text{-OH}$), 3.52 (bs, 6H, $(\text{CH}_3)_2\text{N}$), 2.87 (bs, 1H, OH), 2.50 (m, 2H, $\text{CH}_2\text{-CH}_2\text{OH}$).

15

Example 81


5-(N-6-Dimethylaminopurin-9-yl)-3-pentynyl-1-oxycarbonyl-L-arginine - **Compound #81**



5 Spectral properties were identical with compound #40.

Example 82

N,N-(6-Dimethylaminopurin-9-yl)-7-thioethoxy-ethanol - **Compound #82**




10

^1H NMR (CDCl_3): δ 8.30 (s, 1H, purine), 7.75 (s, 1H, purine), 4.41 (t, 2H, $J = 6.5$, CH_2 linker), 4.11 (bs, 1H, OH), 3.73 (t, 2H, $J = 6.5$, CH_2 linker), 3.51 (bs, 6H, $(\text{CH}_3)_2\text{N}$), 2.99 (t, 2H, $J = 6.5$, CH_2 linker), 2.68 (t, 2H, $J = 6.5$, CH_2 linker).

15

Example 83


N,N-(6-Dimethylaminopurin-9-yl)-7-thioethoxy-
ethoxycarbonyl-L-arginine - **Compound #83**



5 Spectral properties were identical with compound #40.

Example 84

(2S,4S) and (2R,4R)-2-(N,N-Dimethylaminopurin-9-yl)-4-(methoxycarbonyl-D-arginine)-1,3-
oxathiolane - **Compound #84**



10


^1H NMR (CDCl_3 , 300 MHz): δ 8.49 (s, 1H, purine), 8.47 (s, 1H, purine), 6.60 (bs, 1H, NH carbamate), 6.22 (m, 1H, H-2-oxathiolane), 4.26-4.03 (m, 3H), 3.63-3.00 (m, 11H), 2.78-2.69 (m, 2H, H-5-oxathiolane), 1.53-1.40 (m, 4H, $\text{CH}_2\text{-CH}_2\text{-CH}_2\text{NH-C(NH)NH}_2$).

15

Example 85

N,N-(6-Dimethylaminopurin-9-yl)-7-ethoxy-
ethoxyethanol - **Compound #85**


20



^1H NMR (CDCl_3): δ 8.29 (s, 1H, purine), 7.80 (s, 1H, purine), 4.33 (t, 2H, CH_2), 3.82 (t, 2H, CH_2), 3.68 (t, 2H, CH_2), 3.55 (t, 2H, CH_2), 3.50 (m, 6H, $\text{N}(\text{CH}_3)_2$).

Example 86

N,N-(6-Dimethylaminopurin-9-yl)-7-ethoxy-ethoxycarbonyl-D-arginine - **Compound #86**




10

^1H NMR ($\text{DMSO}-d_6$): δ 8.25 (s, 1H, purine), 8.14 (s, 1H, purine), 6.5 (bd, 1H, NH carbamate), 4.37 (t, 2H, CH_2 linker), 4.03 (m, 2H, CH_2 linker), 3.81 (m, 2H, CH_2 linker), 3.72 (m, 1H, $\text{CH}-\text{COOH}$), 3.60 (m, 2H, CH_2 linker), 3.55-3.89 (m, 6H, $\text{N}(\text{CH}_3)_2$), 3.05 (m, 2H, $\text{CH}_2-\text{NH}-\text{C}(\text{NH})\text{NH}_2$), 1.78-1.39 (m, 4H, $\text{CH}_2-\text{CH}_2-\text{CH}_2\text{NH}-\text{C}(\text{NH})\text{NH}_2$).

Example 87


N,N-(6-Dimethylaminopurin-9-yl)-7-ethoxy-
ethoxycarbonyl-L-arginine - Compound #87



5 Spectral properties were identical with compound #86.

Example 88

N-(6-Dimethylamino-8-bromopurin-9-yl)5-pentanol
- Compound #88



10

^1H NMR (CDCl_3) 400 MHz): δ 8.27 (s, 1H, purine), 4.18 (t, 2H, $\text{J}=7.2$, CH_2), 3.64 (t, 2H, $\text{J}=6.3$, CH_2), 3.48 (bs, 6H, $\text{N}(\text{CH}_3)_2$), 2.02 (bs, 1H, OH), 1.85 (quint, 2H, $\text{J}=7.2$, CH_2), 1.63 (quint, 2H, $\text{J}=6.3$, CH_2), 1.46 (m, 2H, CH_2).

15

BIOLOGICAL DATAIN VITRO SCREENING:5 Example 89: Mitogenic Proliferation on Spleen Cell
Suspension

Mitogenic lectin (mitogen) is a protein which binds and cross-links specific cells surface carbohydrate
10 determinants, and will polyclonally stimulate lymphoid cells. Lymphocyte activation by either antigens or mitogens results in intracellular changes and the subsequent development into a lymphoblast. Mitogenic stimulation of lymphocytes *in vitro* is believed to mimic
15 the series of events which occur *in vivo* following their stimulation by specific antigens. PHA, ConA, and PWM, LPS mitogens can be used as a measurement of T cell and B cell activity, respectively.

20 Briefly, spleen mononuclear leukocytes from C57BL/6 mice were incubated in the presence or absence of mitogens with or without tested drugs. After 72 hours or 5 days, ³H thymidine incorporation was recorded as an indication of cell transformation and proliferation.

25

100 µl of a suspension of 2X10⁶ cells/ml (2x10⁵ cells/well) were incubated in presence of PHA or ConA or PWM or LPS at the following concentrations:

30 PHA = 0.01% final concentration - 0.001%

ConA = 2 µg/ml - 1 µg/ml

PWM = 0.2x - 0.02x

LPS = 5 µg/ml - 2 µg/ml

Cells were incubated in presence or absence of drugs for 72 hours. 0.5 or 1 μ Ci of tritiated thymidine (^3H) was added per well the last 18 or 6 hours of incubation respectively. Cells were harvested and counted on a Beta
5 counter.

TABLE 1
(Mitogenic Proliferation)

Compound No.	T (ConA) (M)	B (LPS) (M)
ST-789	0	$1.5-3 \times (10^{-8}-10^{-5})$
#1	$2-4 \times (10^{-8}-10^{-5})$	$2 \times (10^{-6})$
#2	$2-4 \times (10^{-8}-10^{-5})$	0
#3	$2-6 \times 10^{-12}-10^{-6}$	$2-2.5 \times (10^{-8}-10^{-6})$
#7	$2-6 \times (10^{-12}-10^{-8})$	0
#9	$2-3.5 \times (10^{-12}-10^{-6})$	

10

Example 90: **Cytotoxic T Lymphocytes (CTL) and Mixed**
Lymphocyte Reaction (MLR) Assays

15 Mixed lymphocyte reaction is an *in vitro* counterpart of the allograft rejection. Briefly, T cell response was obtained when cells taken from two inbred strains from two outbred individuals of any species were mixed *in vitro* in culture. To have a unidirectional response, the
20 proliferation of either cell type may be blocked with X-irradiation or mitomycin C treatment.

After 4 days incubation, ^3H thymidine uptake and cytotoxicity assay (CTL) were performed.

25

3 C57Bl/6 mice and 3 DBA/2 mice were killed and lymphocytes prepared using lympholyte M. The cell concentration was adjusted to 10×10^6 cell/ml for each lysis. DBA/2 cells were irradiated with 3000 Rads. 1 ml of the C57 cells + 1ml of the DBA/2 cells + 1 ml of the drug at 3 different concentrations were incubated together for 5 days. Positive control was IL-2 at 15 ng/ml final. After 5 days, the CTL and MLR tests were carried out.

10 MLR

The cells were resuspended and 100 μ l of cell suspension were deposited in each of the 96 wells in the plate, 50 μ l of thymidine at 20 μ Ci/ml was added for 6 hrs. The cells were then collected and counted using a beta counter.

15

CTL

P815 target cells were labelled with Cr^{51} . After labelling, the cells were resuspended to 5×10^4 cells/ml. Effector cells were adjusted to 2.5×10^6 cells/ml, and then diluted 1:2 and 1:4 to obtain the necessary effector to target ratios:

50:1 (2.5×10^6 cells/ml: 5×10^4 cell/ml)
25:1 (1.25×10^6 cells/ml: 5×10^4 cells/ml)
25 12.5:1 (0.625×10^6 cells/ml: 5×10^4 cells/ml)

100 μ l of target cells + 100 μ l Of T cells were incubated for 4 hrs and then 100 μ l of supernatant was counted using a gamma counter.

30

TABLE 2
(CTL and MLR Assays)

Compound No.	CTL (M)	MLR (M)
ST 689	++++ (10 ⁻⁷ M) ^P	1.6x (10 ⁻⁵ M) ^P
ST 789	++ (10 ⁻⁷)	2-3x(10 ⁻⁹ -10 ⁻⁵)
#III	+++ (10 ⁻⁷ M)	1.5-2.5x (10 ⁻⁹ -10 ⁻⁵ M)
#V	+++ (10 ⁻⁷ M)	1.5-2x (10 ⁻⁷ -10 ⁻⁵ M)
#1	++++ (10 ⁻⁹)	1.5-4x(10 ⁻⁹ -10 ⁻⁵)
#2	0	1.5-2x(10 ⁻⁷ -10 ⁻⁵)
#3	+ (10 ⁻⁵)	1.5x(10 ⁻⁹ -10 ⁻⁵)
#3a	+++ (10 ⁻⁹ -10 ⁻⁷ M)	1.5-2.9x (10 ⁻⁹ -10 ⁻⁵ M)
#5	+ (10 ⁻⁷)	1.5-2x(10 ⁻⁷ -10 ⁻⁵)
#5a	++ (10 ⁻⁷ -10 ⁻⁵ M)	1.5-2x (10 ⁻⁹ -10 ⁻⁶ M)
#6	+++ (10 ⁻⁹)	1.5-3x(10 ⁻⁹ -10 ⁻⁵)
#7	+++ (10 ⁻⁹)	1.5-2x(10 ⁻⁹ -10 ⁻⁶)
#7a	++++ (10 ⁻⁹ M) ^P	2x (10 ⁻⁹ -10 ⁻⁵ M) ^P
#8	++++ (10 ⁻⁹)	1.5-2x(10 ⁻⁹ -10 ⁻⁵)
#11	++ (10 ⁻⁷)	2-2.5x(10 ⁻⁷ -10 ⁻⁵)
#19	++ (10 ⁻⁷ M) ^P	0 ^P
#20	++ (10 ⁻⁵)	
#51	++ (10 ⁻⁷ M)	1.5-2x (10 ⁻⁹ -10 ⁻⁶ M)
#59	++ (10 ⁻⁹ M)	2-2.4x (10 ⁻⁹ -10 ⁻⁵ M)
#60	+ (10 ⁻⁷ M)	1.7-2x (10 ⁻⁹ -10 ⁻⁵ M)

5 For CTL Activity, the data expressed is as a % increase compared to IL-2. IL-2 is 100%. 0 represents less than 20%, + represents 20-40%, ++ represents 40-60%, and +++ represent 60-80%, and ++++ represents 80+. P = Preliminary result

IN VIVO/EX VIVO SCREENING**Example 91: Immunophenotyping**

5 After *in vitro* drugs analysis, the drugs were evaluated on whole blood for drug stability and toxicity. Furthermore, *in vivo* /*ex vivo* analysis was performed on normal and cyclophosphamide immunosuppressed animals plus 5Fu-treated animals. Cell immunophenotyping was performed on mouse-
10 treated blood and spleen. The following cell surface antigens were analyzed:
CD3 (all T cells), CD4 (T helper/inducer, binds class II-restricted T cells), CD8a (cytotoxic T cells, CTL adhesion), CD11a (T, B, NK, some stem cells, CTL adhesion
15 anti LFA-1 α), MAC-1 (monocyte/macrophage), NK (natural killer cells), Ly5 (B cells), CD45 (all leukocytes, protein tyrosine phosphates), and TCR (T cell receptor).

C57BL/6 mice (6-8 weeks old) were injected daily for 4
20 consecutive days, sacrificed at day 5 and immunophenotyping was performed on blood and spleen cells.

The cells were washed twice in PBS, resuspended in 1 ml of RPMI 2% FBS, and incubated for 45 min. on ice with
25 monoclonal antibody. The cells were washed once, fixed with 1% paraformaldehyde, then analyzed using XL Coulter[®] counter. Results are presented in Table 3a and 3b.

TABLE 3a

**Immunophenotyping On Blood Cells
Of Compound #1 Treated-Mice (N=10)**

Cell marker		Control	25 mg/kg	50 mg/kg
CD8+	mean	6.66	10.11	8.65
	STD	2.09	2.69	1.39
	p		0.005	0.02
CD45+	mean	6.01	5.90	8.14
	STD	0.98	1.39	1.35
	p		0.5	0.005
NK+	mean	3.43	5.84	3.25
	STD	0.76	2.08	0.57
	p		0.02	0.289
CD3+	mean	9.60	13.71	9.68
	STD	2.79	2.68	3.59
	p		0.015	0.4

5

TABLE 3b

**Immunophenotyping On Spleen Cells Of Compound #1
Treated-Mice (N=10)**

Cell marker		Control	25 mg/kg	50 mg/kg
TCR+	mean	38.93	39.78	45.09
	STD	3.83	7.61	7.34
	p		0.421	0.035
Ly5	mean	55.49	54.08	50.35
	STD	3.44	7.30	6.72
	p		0.37	0.034

TABLE 4

**Immunophenotyping On Blood Cells Of Mice Treated With
Compound #1 In Combination With
Cyclophosphamide (N=4)**

5

Cell marker		cyclo- phosphamide 100 mg/kg	CY + cpd #1 25 mg/kg	CY + cpd #1 50 mg/kg
CD8+	mean	15.05	13.25	20.8
	STD	3.89	0.07	0.85
	p		0.33	0.05
CD45+				

Spleen: no effect

10

TABLE 5a

**Immunophenotyping On Blood Cells Of Mice Treated
With Compound #1 In Combination
With 5 Fluorouracil (N=4)**

Cell marker		5 FU (80 mg/kg)	5 FU + cpd #1 25 mg/kg	5 FU + cpd #1 50 mg/kg
CD8+	mean	6.66	10.11	8.65
	STD	2.09	2.69	1.39
	p		0.005	0.022
CD45+				
NK+	mean	3.24	3.58	4.12
	STD	0.66	1.01	0.74
	p		0.38	0.01

15

TABLE 5b

**Immunophenotyping On Spleen Cells Of Mice Treated
With Compound #1 In Combination
With 5 Fluorouracil (N=4)**

Cell marker		5 FU	5 FU + cpd #1	5 FU + cpd #1
		(80 mg/kg)	25 mg/kg	50 mg/kg
CD4+	mean	10.0	13.19	12.06
	STD	1.98	3.19	2.27
	p		0.015	0.04
CD45-	mean	4.22	3.32	3.17
	STD	0.5	0.45	0.36
	p		0.0005	0.0001

5

ANTITUMOR ASSESSMENT PROTOCOL

The compounds were tested for tumor growth control using
10 the following procedures.

Example 92: Effect of compound #1 on growth of breast
 carcinoma in combination with
 cyclophosphamide.

15

Balb/C Mice (n=5/Gr) were used along with DA-3 mammary
carcinoma cell line. The mice were treated from -2 to 13
days. Animals were monitored for tumor takes/tumor size
and body weights for three weeks from Day 0 until Day 21.
20 D0 was the day of tumor cell inoculation and D21 was the
day of experiment termination.

Parameters of effect were measured by inhibition of tumor
outgrowth and growth rate [tumors measured along the

longest axis (length) and the perpendicular shortest axis (width) and the tumor volumes (T.V. \pm S.E.) was calculated by the formula $T.V. = \text{length (cm)} \times (\text{width cm})^2 / 2$.] assessment of body weight loss.

5

The statistical significance of difference between tumor takes and tumor sizes of control-untreated and drug-treated groups is estimated using the Chi-square and Student's t tests respectively with significance

10 determined at $p < 0.05$.

The mice were divided into the following 5 groups:

Gr.1 - Normal Saline (0.2 ml/mouse i.p. starting at D2)

15 Gr.2 - CY (100 mg/kg single bolus i.v. at D0)

Gr.3 - Compound #1 (25 mg/kg i.p. starting at D2)

Gr.4 - Compound #1 (50 mg/kg i.p. starting at D2)

Gr.5 - CY (100 mg/kg i.v. at D0 + compound #1 50 mg/kg i.p. starting at D2)

20

Results are presented in Table 6 and Figures 1 and 2.

TABLE 6
Effect of compound #1 treatment on
Tumor Outgrowth

Group/Day	4	6	8	10
Gr.1: saline	5/5*	5/5	5/5	5/5
Gr.2: CY @ 100mg/kg	5/5	5/5	5/5	5/5
Gr.3: #1 @ 25mg/kg	2/5†	2/5†	3/5	4/5
Gr.4: #1 @ 50mg/kg	3/5	3/5	3/5	3/5
Gr.5: CY @ 100mg/kg + #1 @ 50mg/kg	4/5	5/5	5/5	5/5

* Tumor takes= # tumor-bearing mice/total # of mice

5 † p<0.05 by Chi-square test

Example 93: Evaluation of Compound #1 in combination with cyclophosphamide (cytoxan) (CTX, 20 mg/kg) against DA-3 mammary carcinoma.

10

Combination of compound #1 (25 and 50 mg/kg i.p. daily) plus CTX (20 mg/kg i.v. single bolus) was evaluated against day 4 established DA-3 tumors.

15 Results showed no significant effect of combination treatment of compound #1 (at 25 mg/kg) plus CTX. However, a significant but transient effect was observed with CTX plus compound #1 at 50 mg/kg from day 9 until day 18 (Figure 3). The decay of the positive anti-tumor effect is
20 possibly due to the generation of T-suppressor cells at the later stage of tumor growth. No significant body weight loss was observed (Figure 4).

Example 94: Evaluation of Compound #1 in combination with cyclophosphamide (cytoxan) (CTX, 28 mg/kg) against DA-3 mammary carcin ma.

In another experiment, the CTX treatment was prolonged.
5 Balb/c mice were injected s.c. with 5×10^5 DA-3 tumor cells at day 0. At day 4 when established tumors appeared, tumor-bearing animals were randomized (n=11/gr.) and injected with CTX (at 28 mg/kg) i.v. bolus injections at days 4, 11, and 18. Treatment with compound #1 was
10 initiated using standard treatment regimen of daily i.p. injections at 50 mg/kg starting from day 2 until day 28.

Results of this experiment (Table 7) show a highly statistically significant (p, 0.001-p<0.005) anti-tumor
15 effect of the compound #1 (BCH-1393) + CTX combination treatment from day 11 until day 30 of tumor growth. No significant body weight loss was observed (Table 8).

Example 95: Evaluation of compound #1 in combination
20 with 5FU against colon adenocarcinoma.

C57BL/6 mice 6-8 weeks old (n=7-9/gr) were injected with 3×10^5 MC38 colon adenocarcinoma cells s.c. on day 0. On day 7, tumor-bearing mice were randomized and injected with
25 5FU at 20 mg/kg either alone or in combination with levamisole at 20 mg/kg i.p. or with compound #1 at 25 and 50 mg/kg i.p. over a four week period. During this period, animals were treated for 5 consecutive days, untreated for 2 days, and treated again for 5 consecutive days per week
30 for 4 weeks.

Results of this experiment show a significant dose-dependent anti-tumor effect following compound #1 (at 50 and 25 mg/kg) + 5FU (20 mg/kg) compared to control untreated group (Figure 5). The anti-tumor effect of 5FU +
5 Compound #1 (at 50 mg/kg) was markedly better than that of 5FU + Levamisole. A moderate anti-tumor response was observed following treatment with 5FU (20 mg/kg) alone or with 5FU (20 mg/kg) plus Levamisole (20 mg/kg). This may be due to the fact that 20 mg/kg represents a suboptimal
10 dose of 5FU for MC38 colon adenocarcinoma.

Example 96: In vivo toxicity of Compound #1

The objective of this study was to find the toxic dose of compound #1 after repeated intravenous injections in
15 Fisher male and female rats.

Groups of 3 male rats, and 3 female rats were injected daily i.v. for 5 consecutive days. A first group received 500 mg/kg, a second group 250 mg/kg, and a third group 125
20 mg/kg. In addition, one male and one female were injected with 1000 mg/kg. An untreated group (male and female) was included in the experiment. For all doses a constant volume of 0.1 ml/100g was used. Injections were started on day 0 and continued until day 4 (5 days). During
25 treatment, weight changes were recorded daily and the rats were observed for at least 1 hour post-injection for signs of drug effect. On day 8, the rats were euthanatized and a macroscopic examination of the internal organs was performed.

30

Both rats (1 male and 1 female) injected with 1000 mg/kg i.v. showed severe colonic convulsions and died within 10

minutes. With 500 mg/kg, all rats were observed to have twitches of the torso area, tremors of the forepaws and jumping episodes. These signs lasted less than 1 hour and were comparable after each of the five injections. The growth curves of the animal were not affected when compared to controls. With the two lower doses (250 mg/kg and 125 mg/kg), no abnormal signs were observed at any time during dosing and the growth curves were normal (Figures 6 and 7). No drug induced changes were noted on necropsy of these animals.

Compound #1 is well tolerated when injected i.v. in Fisher rats. A dose of 250 mg/kg injected for 5 consecutive days produced no signs of toxicity. The compound caused colonic convulsions and was lethal at the dose of 1000 mg/kg. A dose of 500 mg/kg produced some short lasting abnormal signs but no lethality of effects on the growth of the animals.

20 CONCLUSIONS

From the data, *in vitro*, the compounds of the invention, in particular compound #1, appears to activate T cells (including CTL's) and B cells.

25

In vivo, the compound of the invention, in particular compound #1, increases the number of CTL's.

The compounds of the present invention, in particular compound #1, appear to be well tolerated.

30

Compound #1 appears to inhibit tumor outgrowth in combination with cyclophosphamide against mouse mammary carcinoma *in vivo*.

- 5 Compound #1 appears to inhibit tumor outgrowth in combination with 5FU against mouse colon adenocarcinoma *in vivo*.

Table 7

balb-c mice, 5.0×10^5 sc DA-3 cells p #28, testing compound #1 with Cytoxan injections of cells April 17th, treatment with compound #1 started on April 20th measurement and treatment with Cytoxan started on April 21th, 1995,
Data of tumor sizes including mice with tumor only

DAY	4	7	9	11	14	16	18	21	23	25	28	30
Gr #1 saline ip (Days 3-20)	3.5 n=11/11	11.4 n=11/11	20.3 n=11/11	34.4 n=11/11	61.9 n=11/11	95.6 n=11/11	77.3 n=11/11	82.9 n=11/11	127.3 n=11/11	160.7 n=11/11	122.9 n=11/11	204.9 n=11/11
Gr #2 CTX 28mg/kg ip (Days 4, 11, 18)	4.3 n=11/11	10.6 n=11/11	18.6 n=11/11	30.7 n=11/11	50.8 n=11/11	84.8 n=11/11	63.4 n=11/11	88.6 n=11/11	93.4 n=11/11	106.3 n=11/11	120.9 n=11/11	161.8 n=11/11
Gr #3 BCH-1383 60mg/kg iv (Days 3-20)	0.7017 n=11/11	0.7422 n=11/11	0.7332 n=11/11	0.8806 n=11/11	0.3110 n=11/11	0.1182 n=11/11	0.2337 n=11/11	0.4226 n=11/11	0.0503 n=11/11	0.0372 n=11/11	0.0519 n=11/11	0.0453 n=11/11
Gr #4 BCH-1383 60mg/kg ip (Days 3-28) + CTX 28mg/kg iv (Days 4, 11, 18)	2.7 n=11/11	10.2 n=11/11	18.1 n=11/11	28.2 n=11/11	50.1 n=11/11	89.5 n=11/11	66.3 n=11/11	84.2 n=11/11	131.4 n=11/11	130.9 n=11/11	162.5 n=11/11	187.2 n=11/11
sem	1.01	2.87	4.46	8.82	10.21	12.80	16.45	18.03	26.55	29.51	28.81	36.09
p value	0.6480	0.7141	0.6927	0.6084	0.3888	0.4488	0.8316	0.7938	0.8174	0.4326	0.4087	0.6343
mice number	11	11	11	11	11	11	11	11	11	11	11	11
sem	1.40	1.85	3.44	3.77	5.58	6.48	8.82	9.80	12.67	13.57	13.38	16.05
p value	0.9835	0.0883	0.1186	0.0085	0.0014	0.0031	0.0025	0.0102	0.0018	0.0066	0.0017	0.0017
mice number	11	11	11	11	11	11	11	11	11	11	11	11


Table 8

balb-c mice, 5.0×10^5 sc DA-3 cells p #28, testing compound #1 with Cytoxan injections of cells April 17th, treatment with compound #1 started on April 20th, measurement and treatment with Cytoxan started on April 21th, 1995,
Data of body weight (including every mice in the group)

DAY	4	7	9	11	14	16	18	21	23	25	28	30
Gr #1 saline ip (Days 3-20)	19.2 n=11/11	19.7 n=11/11	19.6 n=11/11	19.8 n=11/11	19.3 n=11/11	19.8 n=11/11	19.5 n=11/11	19.6 n=11/11	19.7 n=11/11	19.8 n=11/11	19.8 n=11/11	20.0 n=11/11
Gr #2 CTX 28mg/kg ip (Days 4, 11, 18)	0.25 n=11/11	0.34 n=11/11	0.32 n=11/11	0.30 n=11/11	0.31 n=11/11	0.31 n=11/11	0.27 n=11/11	0.27 n=11/11	0.26 n=11/11	0.28 n=11/11	0.26 n=11/11	0.31 n=11/11
Gr #3 BCH-1383 60mg/kg iv (Days 3-20)	19.2 n=11/11	19.8 n=11/11	19.8 n=11/11	19.9 n=11/11	19.2 n=11/11	19.7 n=11/11	19.6 n=11/11	19.8 n=11/11	19.7 n=11/11	20.1 n=11/11	20.3 n=11/11	20.4 n=11/11
Gr #4 BCH-1383 60mg/kg ip (Days 3-28) + CTX 28mg/kg iv (Days 4, 11, 18)	19.2 n=11/11	19.8 n=11/11	19.8 n=11/11	19.9 n=11/11	19.2 n=11/11	19.7 n=11/11	19.6 n=11/11	19.8 n=11/11	19.7 n=11/11	20.1 n=11/11	20.3 n=11/11	20.4 n=11/11
sem	1.0000	0.8421	0.4488	0.4040	1.0000	0.8403	0.8208	0.8408	1.0000	0.8141	0.7271	0.431281
p value	0.27	0.33	0.39	0.32	0.33	0.26	0.37	0.32	0.34	0.26	0.29	0.30
mice number	11	11	11	11	11	11	11	11	11	11	11	11
sem	0.27	0.33	0.39	0.32	0.33	0.26	0.37	0.32	0.34	0.26	0.29	0.30
p value	0.1704	0.2144	0.7352	0.1309	0.5701	0.8936	0.2023	0.4121	0.2384	0.5897	0.8350	1.000
mice number	11	11	11	11	11	11	11	11	11	11	11	11
sem	19.7	19.2	19.1	19.0	18.9	19.6	19.3	19.8	19.6	19.6	19.4	19.3
p value	0.3721	0.1904	0.3453	0.0884	0.1847	0.3283	0.4383	0.0508	0.0117	0.4582	0.2201	0.1050
mice number	11	11	11	11	11	11	11	11	11	11	11	11

WE CLAIM:

1. A compound of formula I:



5

or pharmaceutically acceptable derivatives thereof,
wherein

R₁ is selected from the group consisting of hydrogen;

10 C₁₋₁₆ alkyl; halogen; substituted or unsubstituted
thiol; unsubstituted or substituted amino; and OR⁸
wherein R⁸

is selected from the group consisting of hydrogen, C₁₋₁₆
alkyl, C₁₋₈ acyl, and C₇₋₁₈ aryl;

15 R₂ and R₃ are independently selected from the group
consisting of hydrogen; C₁₋₄ alkyl; amino; substituted
or unsubstituted thiol; and halogen; and

R₄ is selected from the group consisting of a linear or
cyclic carbon chain of the formula (CH₀₋₂)₀₋₂₀ -X¹²
20 optionally interrupted with one or more heteroatom,
and optionally substituted with one or more =O, or
=S, and

wherein X¹², is selected from the group consisting of
hydroxy, an aminoalkyl group, an amino acid, or a
25 peptide of 2-8 amino acids,

with the proviso that, when R₁ is NH₂, and R₄ is
pentyloxy carbonyl-L-arginine, then R₂ is not
hydrogen, and



when R_1 is OH, and R_4 is pentyloxycarbonyl-L-arginine,
then R_2 is not NH_2 .

2. The compound according to claim 1, wherein R_4 is
5 $(CH_{0-2})_{1-8}-X^{12}$, wherein X^{12} is OH.
3. The compound according to claim 1, wherein R_4 is $(CH_2)-$
L -O-CO- X^{12} , wherein L is a linear or cyclic carbon
chain optionally interrupted with one or more O, S, or
10 NH.
4. The compound according to claim 1, wherein X^{12} is
 $(CH_2)_mNH_2$ wherein m is an integer between 1 and 6.
- 15 5. The compound according to claim 4, wherein n is 2.
6. The compound according to claim 3, wherein X^{12} is a
naturally occurring amino acid in the D- or L-
configuration.
- 20 7. The compound according to claim 6, wherein said amino
acid is selected from the group consisting of:
arginine, glycine, alanine, glutamic acid, valine,
ornithine, or citrulline, or conservative substitutions
25 thereof.
8. The compound according to claim 7, wherein said amino
acid is D-arginine.
- 30 9. The compound according to claim 7, wherein said amino
acid is L-arginine.
10. The compound according to claim 3, wherein X^{12} is
selected from a peptide of 2 to 8 amino acids.


11. The compound according to claim 10, wherein said peptide is Val-Pro-Leu, or Ile-Pro-Ile, or conservative substitutions thereof.
- 5 12. The compound according to claim 3, wherein L is selected from: $-(CH_2)_n-$, $-(CH_2)_m-H-(CH_2)_m-$, and $(CH_2)_m-C\equiv C-(CH_2)_m-$, wherein H is O, S, or NH, n is an integer between 1 and 6, and m is an integer between 1 and 3.
- 10 13. The compound according to claim 3, wherein L is selected from: phenyl, cyclohexyl, dioxolanyl, oxathiolanyl, and cyclopentyl.
- 15 14. The compound according to claim 1, wherein when R_1 is C_{1-16} alkyl, R_1 is an aromatic or non aromatic ring optionally interrupted with one or more heteroatom, and optionally substituted with one or more heteroatom, hydroxy, halogen, C_{1-16} alkyl, C_{1-16} acyl, C_{6-12} aryl, 20 nitro, or substituted or unsubstituted amino.
15. The compound according to claim 1, wherein R_1 is selected from the group consisting of: hydrogen, halogen, C_{1-6} alkyl, unsubstituted or substituted amino, 25 OH, and OC_{1-6} alkyl, SH, or SC_{1-6} alkyl.
16. The compound according to claim 15, wherein said halogen is chloro.
- 30 17. The compound according to claim 15, wherein said unsubstituted or substituted amino is represented by formula NR^5R^6 wherein R^5 and R^6 are independently selected from the group consisting of hydrogen, C_{1-4}

alkyl, C₁₋₄ alkoxy, C₁₋₄ acyl, substituted or unsubstituted amino, and C₆₋₁₀ aryl.

18. The compound according to claim 17, wherein R₁ is
5 selected from the group consisting of:



, or



, wherein R₂₀ is H or methyl.

- 15 19. The compound according to claim 15, wherein R₁ is OCH₃,
or SCH₃.

20. The compound according to claim 1, wherein R₂ and R₃ are
independently selected from the group consisting of:
20 Cl, Br, I, and F.

21. The compound according to claim 20, wherein R₂ and R₃
are independently Cl, or Br.

- 25 22. The compound according to claim 21, wherein R₂ is Cl.

23. The compound according to claim 21, wherein R₃ is Br.

24. The compound according to claim 1, wherein R₂ is NH₂.

25. The compound according to claim 1, wherein R_3 is SH, or SCH_3 .
26. The compound according to claim 1, wherein R_1 is
5 $N(CH_3)_2$; R_2 and R_3 are hydrogen; and R_4 is
pentyloxycarbonyl-D-arginine, or pharmaceutically
acceptable derivatives thereof.
27. The compound according to claim 1 selected from the
10 group consisting of:
- Compound #IIIN-(6-Chloropurin-9-yl)-5-pentanol
Compound #V N-(6-N,N-Dimethylaminopurin-9-yl)-
pentanol
Compound #1 N,N-Dimethylaminopuriny1 Pentoxycarbonyl
15 D-Arginine
Compound #2 N,N-Dimethylaminopuriny1 Pentoxycarbonyl
L-Arginine
Compound #3 N-Monomethylaminopuriny1 Pentoxycarbonyl
D-Arginine
20 Compound #3a N-(6-N-Methyl-Aminopurin-9-yl)-pentanol
Compound #4 N-Monomethylaminopuriny1 Pentoxycarbonyl
L-Arginine
Compound #5 Aminopuriny1 Pentoxycarbonyl D-Arginine
Compound #5a N-(6-Aminopurin-9-Yl) 5-Pentanol
25 Compound #6 Aminopuriny1 Pentoxycarbonyl L-Arginine
Compound #7 Hydrazinopuriny1 Pentoxycarbonyl D-
Arginine
Compound #7a N-(6-Hydrazinopurin-9-yl) 5-Pentanol
Compound #8 Hydrazinopuriny1 Pentoxycarbonyl L-
30 Arginine;
Compound #9 Chloropuriny1 Pentoxycarbonyl D-Arginine;
Compound #10 Chloropuriny1 Pentoxycarbonyl L-Arginine;
Compound #11 Hydroxypuriny1 Pentoxycarbonyl D-
Arginine;

- Compound #12 Mercaptopurinyl Pentoxycarbonyl D-Arginine;
- Compound #13 Mercaptopurinyl Pentoxycarbonyl L-Arginine;
- 5 Compound #14 N,N-Dimethylaminopurinyl Pentoxycarbonyl Glycine;
- Compound #15 N,N-(6-Dimethylaminopurin-9-yl)-7'-ethoxy-ethoxycarbonyl-D-arginine;
- Compound #16 (2S,4S)-2-(N,N-dimethylaminopurin-9-yl)-10 4-(methyloxycarbonyl-D-arginine)-1,3-dioxolane;
- Compound #17 N-(6-Dimethylamino-8-bromopurinyl)-Pentoxycarbonyl L-Arginine;
- Compound #18 N-(6-dimethylamino-8-bromopurin-9-yl) 7-pentoxycarbonyl-D-arginine;
- 15 Compound #19 N-9-purinyl-5-pentanol;
- Compound #20 N-9-purinyl-7-pentyloxycarbonyl-D-arginine;
- Compound #21 N-9-purinyl-7-pentyloxycarbonyl-L-arginine;
- 20 Compound #22 N,N-Dimethylaminopurinyl Pentoxycarbonyl L-Valyl L-Prolyl L-Leucine;
- Compound #23 N,N-Dimethylaminopurinyl Pentoxycarbonyl L-Isoleucyl L-Prolyl L-Isoleucine;
- Compound #24 N-(6-Cyclopropylaminopurin-9-yl)-5-pentanol;
- 25 Compound #25 N-(6-cyclopropylaminopurin-9-yl)-7-pentyloxycarbonyl-D-arginine;
- Compound #26 N-(6-cyclopropylaminopurin-9-yl)-7-pentyloxycarbonyl-L-arginine;
- 30 Compound #27 N-(6-Azetidinepurin-9-yl)-5-pentanol;
- Compound #28 N-(6-Azetidinepurin-9-yl)-7-pentyloxycarbonyl-D-arginine;
- Compound #29 N-(6-Azetidinepurin-9-yl)-7-pentyloxycarbonyl-L-arginine;

- Compound #30 trans-(N-6-chloropurin-9-yl)-4-methyl-cyclohexyl-methanol;
- Compound #31 trans-(N-6-dimethylaminopurin-9-yl)-4-methyl-cyclohexyl-methanol;
- 5 Compound #32 trans-(N-6-dimethylaminopurin-9-yl)-4-methyl-cyclohexyl-methyloxycarbonyl-D-arginine;
- Compound #33 trans-(N-6-hydroxypurin-9-yl)-4-methyl-cyclohexyl-methanol;
- 10 Compound #34 trans-(N-6-methoxypurin-9-yl)-4-methyl-cyclohexyl-methanol;
- Compound #35 cis-(N-6-dimethylaminopurin-9-yl)-4-methyl-cyclohexyl-methanol;
- Compound #36 cis-(N-6-dimethylaminopurin-9-yl)-4-methyl-cyclohexyl-methyloxycarbonyl-D-arginine;
- 15 Compound #37 N-(6-dimethylaminopurin-9-yl) 7-pentoxycarbonyl-D-citrulline;
- Compound #38 N-(6-methylaziridinepurin-9-yl)-5-pentanol;
- Compound #39 racemic N-(6-methylaziridine purine-9-yl)-7-pentyloxycarbonyl-D-arginine;
- 20 Compound #40 N,N-(6-Dimethylaminopuriny1-9-yl)-7-thioethoxy-ethoxycarbonyl-D-arginine;
- Compound #41 Meta-(N-6-dimethylaminopuriny1-9-yl) methyl-benzyloxycarbonyl-D-arginine;
- 25 Compound #42 5-(N-6-Dimethylaminopuriny1-9-yl)-3-pentynyl-1-oxycarbonylD-arginine;
- Compound #43 Racemic N-[6-(1-methyl-2-acetoxy)-ethylaminopurin-9-yl]-5-pentanol;
- Compound #44 Racemic N-[6-(1-methyl-2-acetoxy), ethylaminopurin-9-yl]-7-pentyloxy-carbonyl-D-arginine;
- 30 Compound #45 N-(2,6-Dichloropurin-9-yl)-5-pentanol;
- Compound #46 N-(2,6-Dichloropurin-9-yl)-7-pentyloxycarbonyl-D-arginine;

- Compound #47 N-(2,6-Dichloropurin-9-yl)-7-pentyloxycarbonyl-L-arginine;
- Compound #48 N-(2-Amino, 6-N, N-Dimethylaminopurin-9-yl)-5-pentanol;
- 5 Compound #49 N-(6-dimethylamino-8-methylthiopurin-9-yl) 5-pentanol;
- Compound #50 N-(6-dimethylamino-8-methylthiopurin-9-yl) 7-pentoxycarbonyl-D-arginine;
- Compound #51 N-(6-methoxypurin-9-yl) 5-pentanol;
- 10 Compound #52 N-(6-methoxypurin-9-yl) 7-pentoxycarbonyl-D-arginine;
- Compound #53 N-(2-chloro-6-methoxypurin-9-yl)-7-pentyloxycarbonyl-D-arginine;
- Compound #54 N-(6-dimethylaminopurin-9-yl) 7-pentoxycarbonyl-D-ornithine;
- 15 Compound #55 N-(6-dimethylaminopurin-9-yl) 7-pentoxycarbonyl-L-ornithine;
- Compound #56 N-(6-dimethylaminopurin-9-yl) 7-pentoxycarbonyl-L-valine;
- 20 Compound #57 N-(6-dimethylamino-9-yl) 7-pentoxycarbonyl-D-valine;
- Compound #58 N(N,N-dimethylaminopurin-9-yl)-7-pentyloxycarbonylethylamine hydrochloride;
- Compound #59 N-(6-Mercaptopurin-9-yl)-pentanol;
- 25 Compound #60 N-(6,-N-Methylthiopurin-9-yl)-pentanol;
- Compound #61 N-(6-chloropurin-9-yl) 4-butanol;
- Compound #62 N-(6-dimethylaminopurin-9-yl) 4-butanol;
- Compound #63 N-(6-dimethylaminopurin-9-yl)-6-butoxycarbonyl-D-arginine;
- 30 Compound #64 N-(6-dimethylaminopurin-9-yl)-6-butoxycarbonyl-L-arginine;
- Compound #65 N-(6-chloropurin-9-yl)-6-hexanol;
- Compound #66 N-(6-N,N-dimethylaminopurin-9-yl)-6-hexanol;

- Compound #67 N-(6-N,N-dimethylaminopurin-9-yl)-8-hexyloxycarbonyl-D-arginine;
- Compound #68 N(6-N,N-dimethylaminopurine-9-yl)-8-hexyloxycarbonyl-L-arginine;
- 5 Compound #69 cis-(N-6-hydroxypurin-9-yl)-4-methyl-cyclohexyl-methanol;
- Compound #70 cis-(N-6-hydroxypurin-9-yl)-4-methyl-cyclohexyl-methyloxycarbonyl-D-arginine;
- Compound #71 trans-(N-6-hydroxypurin-9-yl)-4-methyl-
- 10 cyclohexyl-methyloxycarbonyl-D-arginine;
- Compound #72 N-(6-N,N dimethylaminopurin-9-yl)-5-pentylamine hydrochloride salt;
- Compound #73 N-(6-methylaziridinepurin-9-yl)-7-pentyloxycarbonyl-L-arginine;
- 15 Compound #74 (2S,4S)-2-(N,N-Dimethylaminopurin-9-yl)-4-hydroxymethyl-1,3-dioxolane;
- Compound #75 (1S,3R) and (1R,3S)-1-(N-6-Dimethylaminopurin-9-yl)methyl-3-cyclopentane methanol;
- 20 Compound #76 (1S,3R) and (1R,3S)-1-(N-6-Dimethylaminopurin-9-yl)methyl-3-(methyloxycarbonyl-D-arginine)cyclopentane;
- Compound #77 N,N-(6-Dimethylaminopurin-9-yl)-7-ethylaminoethanol;
- 25 Compound #78 N,N-(6-Dimethylaminopurin-9-yl)-7-ethylaminoethoxycarbonyl-D-arginine;
- Compound #79 N,N-(6-Dimethylaminopurin-9-yl)-7-ethylaminoethoxycarbonyl-L-arginine;
- Compound #80 5-(N-6-Dimethylaminopurin-9-yl)-3-pentyn-
- 30 1-ol;
- Compound #81 5-(N-6-Dimethylaminopurin-9-yl)-3-pentynyl-1-oxycarbonyl-L-arginine;
- Compound #82 N,N-(6-Dimethylaminopurin-9-yl)-7-thioethoxy-ethanol;

- Compound #83 N,N-(6-Dimethylaminopurin-9-yl)-7-thioethoxy-ethoxycarbonyl-L-arginine;
Compound #84 (2S,4S) and (2R,4R)-2-(N,N-Dimethylaminopurin-9-yl)-4-(methoxycarbonyl-D-arginine)-1,3-oxathiolane;
5 Compound #85 N,N-(6-Dimethylaminopurin-9-yl)-7-ethoxy-ethoxyethanol;
Compound #86 N,N-(6-Dimethylaminopurin-9-yl)-7-ethoxy-ethoxycarbonyl-D-arginine;
10 Compound #87 N,N-(6-Dimethylaminopurin-9-yl)-7-ethoxy-ethoxycarbonyl-L-arginine; and
Compound #88 N-(6-Dimethylamino-8-bromopurin-9-yl)-5-pentanol.
- 15 28. The compound according to claim 27 selected from the group consisting of:
Compound #IIIN-(6-Chloropurin-9-yl)-5-pentanol
Compound #V N-(6-N,N-Dimethylaminopurin-9-yl)-pentanol
20 Compound #1 N,N-Dimethylaminopuriny l Pentoxycarbonyl D-Arginine
Compound #2 N,N-Dimethylaminopuriny l Pentoxycarbonyl L-Arginine
Compound #3 N-Monomethylaminopuriny l Pentoxycarbonyl D-Arginine
25 Compound #3a N-(6-N-Methyl-Aminopurin-9-yl)-pentanol
Compound #5 Aminopuriny l Pentoxycarbonyl D-Arginine
Compound #5a N-(6-Aminopurin-9-Yl) 5-Pentanol
Compound #6 Aminopuriny l Pentoxycarbonyl L-Arginine
30 Compound #7 Hydrazinopuriny l Pentoxycarbonyl D-Arginine
Compound #7a N-(6-Hydrazinopurin-9-yl) 5-Pentanol
Compound #8 Hydrazinopuriny l Pentoxycarbonyl L-Arginine;

Compound #11 Hydroxypurinyl Pentoxycarbonyl D-Arginine;

Compound #19 N-9-purinyl-5-pentanol;

Compound #20 N-9-purinyl-7-pentyloxycarbonyl-D-arginine;

Compound #51 N-(6-methoxypurin-9-yl) 5-pentanol;

Compound #59 N-(6-Mercaptopurin-9-yl)-pentanol; and

Compound #60 N-(6,-N-Methylthiopurin-9-yl)-pentanol.

29. The compound according to claim 28 being compound #1 - N2-(6-dimethylaminopurin-9-yl) 7-pentyloxycarbonyl-D-arginine.

30. A pharmaceutical composition containing a compound according to claim 1, 27, or 29, wherein said compound is present in admixture with a pharmaceutically acceptable carrier.

31. A pharmaceutical composition according to claim 30 wherein compound is present in admixture with another therapeutically active agent.

32. A pharmaceutical composition according to claim 31 wherein said therapeutically active agent is cyclophosphamide.

33. A method for the treatment of immune deficiencies or control of cancer growth comprising the step of administering to a mammal a pharmaceutically acceptable amount of a compound according to claim 1, 27, or 29.

34. A method for increasing the number of cytotoxic T lymphocytes in a mammal, including a human, comprising

the step of administering a pharmaceutically acceptable amount of a compound according to claim 1, 27, or 29.

35. A method for the control of cancer growth in a mammal,
5 including human, comprising the step of administering to a mammal a pharmaceutically acceptable amount of a compound according to claim 29.

36. A method for the control of mammary carcinoma in a
10 mammal, including human, comprising the step of administering to a mammal a pharmaceutically acceptable amount of a compound according to claim 29, in combination with cyclophosphamide.

15 37. A pharmaceutical composition for the treatment of cancer comprising a compound according to claim 1, 27 or 29, in combination with 5-fluorouracil.

38. The pharmaceutical composition according to claim 37
20 wherein said cancer is colon carcinoma.

39. A method for the treatment of cancer in a mammal,
including a human, comprising the step of administering a pharmaceutically acceptable amount of compound
25 according to claim 1, 27, or 29, in combination with 5-fluorouracil.

40. The method according to claim 39, wherein said cancer
is colon carcinoma.

30

41. The method according to claim 39, wherein said compound is administered in an amount ranging from about 1 to about 100 mg/kg.

42. The method according to claim 41, wherein said compound is administered in an amount ranging from about 2 to about 20 mg/kg.
- 5 43. The method according to claim 42, wherein said compound is administered at about 2.5 mg/kg.
44. The method according to claim 39, wherein said 5-fluorouracil is administered in an amount ranging from
10 about 1 to about 50 mg/kg.
45. The method according to claim 44, wherein said 5-fluorouracil is administered in an amount ranging from about 5 to about 20 mg/kg.
- 15 46. The method according to claim 45, wherein said 5FU is administered at about 12 mg/kg.
47. The method according to claim 39, wherein said
20 combination is administered sequentially.
48. The method according to claim 39, wherein said combination is administered simultaneously.
- 25 49. The method according to claim 39, wherein said combination is administered as a single formulation combining 5-FU and said compound.

FIGURE 1
Tumor volume variations, data considering mice with tumors only





FIGURE 2
Body weight variations







FIGURE 4
Variation of body weight








FIGURE 6
Growth curves of compound #1 treated Fisher
male rats and control (5 i.v injections) 6/03/95





INTERNATIONAL SEARCH REPORT

Internat Application No
PCT/CA 95/00356A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D473/00 C07D473/34 C07K5/08 A61K31/52

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07D C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEMICAL ABSTRACTS, vol. 113, no. 9, 27 August 1990, Columbus, Ohio, US; abstract no. 70699k, page 19 ;column R ; see abstract & FARMACO, vol.45, no.1, 1990 pages 39 - 47	1-30
X	CHEMICAL ABSTRACTS, vol. 117, no. 7, 17 August 1992, Columbus, Ohio, US; abstract no. 70282b, page 850 ;column L ; see abstract & THYMUS, vol.19, no.1, 1992 pages S31 - S42	1-29

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

21 November 1995

Date of mailing of the international search report

- 1. 12. 95

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Luyten, H

INTERNATIONAL SEARCH REPORT

Internat Application No
PCT/CA 95/00356

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BIOCHEMISTRY, vol.4, no.1, January 1965 pages 71 - 75 HOWARD J. SCHAEFFER ET AL *Page 72, chart1, formulas 21 and 22* ---	1-30
X	WO,A,88 05437 (CO PHARMA CORPORATION S.R.L.) 28 July 1988 *Document* ---	1,2
X	EP,A,0 260 588 (SIGMA-TAU INDUSTRIE) 23 March 1988 *Document* ---	1-30
A	EP,A,0 291 229 (MERCK & CO. INC) 17 November 1988 *Document* ---	1,30
A	EP,A,0 077 460 (CO PHARMA CORPORATION S.R.L.) 27 April 1983 *Document* ---	1-30
A	EP,A,0 464 009 (SIGMA-TAU INDUSTRIE) 2 January 1992 cited in the application *Document* ---	1-30
A	EP,A,0 506 628 (SIGMA-TAU INDUSTRIE) 30 September 1992 cited in the application *Document* & US,A,5 272 151 (MARZI, MAURO ET AL) ---	1-30
A	CHEMICAL ABSTRACTS, vol. 117, no. 5, 3 August 1992, Columbus, Ohio, US; abstract no. 39631r, page 3 ;column L ; cited in the application see abstract & THYMUS, vol.19, no.1, 1992 ---	1-30
P,A	WO,A,95 13277 (MERRELL DOW PHARMACEUTICALS INC.) 18 May 1995 *Page 68-74: claims ,particularly claim 2* -----	1,30

INTERNATIONAL SEARCH REPORT

Intern. application No.

PCT/CA95/00356

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 33 - 36, 39 - 49 are directed to a method of treatment of
(diagnostic method practised on) the human/animal body, the search has been
carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such
an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internat Application No
PCT/CA 95/00356

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-8805437	28-07-88	AU-B- 605837	24-01-91
		AU-B- 1226588	10-08-88
		DE-A- 3864820	17-10-91
		EP-A, B 0355085	28-02-90
		JP-T- 2501924	28-06-90
EP-A-0260588	23-03-88	AU-B- 593136	01-02-90
		AU-B- 7847187	24-03-88
		CA-A- 1276148	13-11-90
		DK-B- 168570	25-04-94
		JP-A- 63088184	19-04-88
EP-A-0291229	17-11-88	US-A- 4782062	01-11-88
		CA-A- 1276635	20-11-90
		DE-D- 3888999	19-05-94
		DE-T- 3888999	13-10-94
		JP-A- 63297381	05-12-88
EP-A-0077460	27-04-83	AU-B- 8808082	31-03-83
		CA-A- 1258149	01-08-89
		US-A- 4567182	28-01-86
		JP-C- 1679818	13-07-92
		JP-B- 3045074	09-07-91
		JP-A- 58077882	11-05-83
EP-A-0464009	02-01-92	IT-B- 1241452	17-01-94
		JP-A- 4230298	19-08-92
		US-A- 5298621	29-03-94
EP-A-0506628	30-09-92	IT-B- 1244501	15-07-94
		JP-A- 5117275	14-05-93
		US-A- 5272151	21-12-93
US-A-5272151	21-12-93	IT-B- 1244501	15-07-94
		EP-A- 0506628	30-09-92
		JP-A- 5117275	14-05-93
WO-A-9513277	18-05-95	AU-B- 8120794	29-05-95